image
imagewidth (px) 258
933
| latex
stringlengths 198
5.27k
| filename
stringlengths 18
19
|
|---|---|---|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Sample} & \textbf{2 days} & \textbf{3 days} & \textbf{4 days} & \textbf{5 days} & \textbf{6 days} & \textbf{Resting cell} \\
\hline
260/280 & 2.18 & 2.16 & 2.13 & 1.97 & 2.09 & 2.00 \\
\hline
260/230 & 1.61 & 1.57 & 1.65 & 1.41 & 1.60 & 1.52 \\
\hline
Conc. (ng/$\mu$L) & 1329.56 & 762.96 & 563.76 & 324.00 & 336.84 & 594.04 \\
\hline
\end{tabular}}
\end{table}
|
PMC5101243_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Tissue} & \textbf{Treatment} & \textbf{CFU/g tissue a} & \textbf{\#animals K88 detection qPCR} \\
\hline
Colon & T1 & 1.21 $\times$ 104 $\pm$ 2.6 $\times$ 104 & 5/6 b \\
\hline
& T2 & 1.06 $\times$ 103 $\pm$ 1.93 $\times$ 103 & 4/6 \\
\hline
& T3 & 3.42 $\times$ 102 $\pm$ 3.92 $\times$ 102 & 3/6 \\
\hline
& T4 & 1.21 $\times$ 104 $\pm$ 2.6 $\times$ 104 & 2/6 \\
\hline
Ileum & T1 & 1.43 $\times$ 108 $\pm$ 2.02 $\times$ 108 & 2/6 \\
\hline
& T2 & 2.64 $\pm$ 0.19 & 2/6 \\
\hline
& T3 & 2.47 $\times$ 108 $\pm$ 0 & 1/6 \\
\hline
& T4 & 0 & 0/6 \\
\hline
\end{tabular}}
\end{table}
|
PMC5688758_table_10
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{|l|}{\textbf{Myocardial injury}} & \multicolumn{3}{|l|}{\textbf{Mortality at 28 days}} & \multicolumn{3}{|l|}{\textbf{Mortality at 7 days}} \\
\hline
& \textbf{No (n = 21)} & \textbf{Yes (n = 26)} & \textbf{P value} & \textbf{Survivors} & \textbf{Non-survivors} & \textbf{P value} & \textbf{Survivors} & \textbf{Non-survivors} & \textbf{P value} \\
\hline
MR-proADM & 2.5 (2.4) & 5.2 (5.8) & 0.007 & 3.0 (3.4) & 6.3 (6.7) & 0.010 & 3.3 (2.9) & 7.1 (5.2) & 0.002* \\
\hline
CT-proET-1 & 153 (111) & 324 (238) & $<$0.001* & 188 (183) & 289 (247) & 0.027 & 198 (172) & 332 (319) & 0.088 \\
\hline
hsTNT & - & - & - & 51 (85) & 143 (444) & 0.007 & 57 (126) & 146 (388) & 0.033 \\
\hline
Creatinine & - & - & - & 138 (150) & 182 (131) & 0.211 & 122 (129) & 200 (132) & 0.048 \\
\hline
\end{tabular}}
\end{table}
|
PMC4899903_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Strain} & \textbf{Protein name (No.)A} & \multicolumn{3}{|l|}{\textbf{Repeat range}} & \multicolumn{2}{|l|}{\textbf{Variation siteB}} & \multicolumn{4}{|l|}{\textbf{Variation distributionC}} \\
\hline
& & \textbf{Smallest} & \textbf{Largest} & \textbf{Average} & \textbf{D} & \textbf{S} & \textbf{N} & \textbf{M} & \textbf{C} & \textbf{W} \\
\hline
S. aureus & ClfA (36) & 45 & 65 & 52.18 & A,G,E,T,N & N,L & 10–20 & & 10–15 \\
\hline
S. aureus & ClfB (30) & 9.33 & 59 & 37.75 & G,E,N & N & 5–10 & 1–5 \\
\hline
S. aureus & SdrC (28) & 5 & 58.67 & 27.80 & E & N,T & 1–5 & 1–4 \\
\hline
S. aureus & SdrD (27) & 22 & 38.33 & 30.53 & E & C & & & 0–5 \\
\hline
S. aureus & SdrE (28) & 13.33 & 27.67 & 23.73 & E & & 0–3 \\
\hline
S. aureus & Pls (6) & 26.33 & 51.33 & 38.05 & E & A & & & & 2–30 \\
\hline
S. epidermidis & SdrF (4) & 32.67 & 93 & 69.75 & E & A,Y & & & & 12–25 \\
\hline
S. epidermidis & SdrG (9) & 9.33 & 33.33 & 22.63 & A,G & N & & 1–5 & 1–5 \\
\hline
S. epidermidis & SdrH (9) & 15 & 21 & 18.81 & G & A,N & & 1–5 & 1–5 \\
\hline
S. lugdunensis & Fbl (4) & 15.67 & 43.67 & 36.25 & G,N & A & & & & 17–47 \\
\hline
S. haemolyticus & Sdr (1) & 29 & 29 & 29 & & A & 2 & & 29 \\
\hline
S. saprophyticus & SdrI (1) & 142.67 & 142.67 & 142.67 & & A & & & & 111 \\
\hline
S. capitis & SdrX (1) & 34.67 & 34.67 & 34.67 & G,E,C & N,L & 5 & & 8 \\
\hline
S. caprae & SdrZ (1) & 21.33 & 21.33 & 21.33 & G,N & A,Q & & & & 21 \\
\hline
L. plantarum & Sdr (4) & 81 & 267.67 & 181.92 & G,N & A,G & 2–3 & & 2–3 \\
\hline
A. baumannii & Adhesin 1 (1) & 235.67 & 235.67 & 235.67 & & & None \\
\hline
A. baumannii & Adhesin 2 (1) & 167.67 & 167.67 & 167.67 & & A & & 2 \\
\hline
K. pneumoniae & Sdr (1) & 424.33 & 424.33 & 424.33 & E & A & 2 & 14 & & 1 \\
\hline
\end{tabular}}
\end{table}
|
PMC3324548_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \textbf{FS} & \textbf{SS} & \textbf{Control} & \textbf{ANOVA} & \textbf{Tukey’s HSD test} \\
\hline
\multicolumn{6}{|l|}{WAIS-RC} \\
\hline
Verbal IQ & 93.67 (13.97) & 93.95 (14.75) & 110.52 (13.93) & F = 79.45** & FS-control p $<$ 0.001** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.99 \\
\hline
Performance IQ & 79.19 (16.08) & 76.05 (18.53) & 100.82 (15.45) & F = 116.10** & FS-control p $<$ 0.001** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.29 \\
\hline
IQ & 86.69 (13.84) & 85.46 (15.35) & 107.10 (13.89) & F = 125.27** & FS-control p $<$ 0.001** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.77 \\
\hline
\multicolumn{6}{|l|}{WMS-RC} \\
\hline
Immediate logical memory & 6.58 (3.74) & 6.68 (3.52) & 13.22 (3.50) & F = 198.43** & FS-control p $<$ 0.001** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.97 \\
\hline
Delayed logical memory & 4.82 (3.54) & 4.24 (2.94) & 11.08 (3.95) & F = 218.34** & FS-control p $<$ 0.001** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.91 \\
\hline
VFT, valid words & 16.82 (4.83) & 18.61 (4.66) & 22.23 (4.83) & F = 50.44** & FS-control p $<$ 0.001** \\
\hline
& & & & & FS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.007*\# \\
\hline
\multicolumn{6}{|l|}{Trail Test} \\
\hline
TMA: time to completion & 55.78 (18.23) & 56.30 (20.29) & 38.55 (13.32) & F = 59.67** & FS-control p $<$ 0.003** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.97 \\
\hline
TMB-M: time to completion & 84.37 (27.52) & 88.77 (33.80) & 53.14 (14.16) & F = 100.01** & FS-control p $<$ 0.001** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.37 \\
\hline
\multicolumn{6}{|l|}{WCST-M} \\
\hline
Perseverative errors & 10.00 (8.99) & 9.46 (7.96) & 2.89 (2.36) & F = 75.60** & FS-control p $<$ 0.001** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.79 \\
\hline
Categories & 3.54 (2.07) & 3.65 (2.00) & 5.57 (0.81) & F = 84.82** & FS-control p $<$ 0.001** \\
\hline
& & & & & SS-control p $<$ 0.001** \\
\hline
& & & & & FS-SS p = 0.86 \\
\hline
\end{tabular}}
\end{table}
|
PMC5007652_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Gene modules} & \textbf{Method} & \textbf{Mean Squared Error} & \textbf{\# of predictors} & \textbf{Proportion of variance explained(\%)} & \textbf{\# of eQTLs} & \textbf{\# of eQTLs with known gene locations} & \textbf{Proportion of cis eQTLs (\%)} \\
\hline
\\
\hline
\\
\hline
Plum1 & LassoM & 1750411 & 23 & 56.01 & 621 & 69 & 17.39 \\
\hline
& LassoMP & 1639614 & 9 & 52.13 & 243 & 27 & 29.63 \\
\hline
Skyblue & LassoM & 2918151 & 47 & 52.65 & 1269 & 47 & 9.57 \\
\hline
& LassoMP & 2801753 & 2 & 36.68 & 54 & 4 & 50.00 \\
\hline
Saddlebrown & LassoM & 2919870 & 14 & 46.73 & 378 & 28 & 21.43 \\
\hline
& LassoMP & 2675651 & 3 & 47.23 & 81 & 21 & 100.00 \\
\hline
\end{tabular}}
\end{table}
|
PMC5155383_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
& & & \textbf{MAF} & \multicolumn{3}{|l|}{\textbf{Leprosy per se}} & \multicolumn{3}{|l|}{\textbf{MB}} & \multicolumn{3}{|l|}{\textbf{PB}} & \textbf{RegulomeDB} \\
\hline
\textbf{SNP ID} & \textbf{Population*} & \textbf{Allele} & \textbf{(control)} & \textbf{MAF} & \textbf{P\#} & \textbf{OR (95\%CI)} & \textbf{MAF} & \textbf{P\#} & \textbf{OR} & \textbf{MAF} & \textbf{P\#} & \textbf{OR (95\%CI)} & \textbf{Scorea} \\
\hline
rs1061593 & Yuxi & A/G & 0.478 & 0.484 & 0.777 & 1.024 (0.867-1.211) & 0.477 & 0.966 & 0.996 (0.813-1.219) & 0.492 & 0.601 & 1.058 (0.856-1.307) & 1 f \\
\hline
& Pooled & & 0.479 & & 0.801 & 1.017 (0.892-1.160) & & 0.896 & 0.988 (0.831-1.176) & & 0.601 & 1.050 (0.874-1.263) \\
\hline
rs2305666 & Yuxi & C/A & 0.388 & 0.384 & 0.840 & 0.982 (0.827-1.167) & 0.376 & 0.619 & 0.948 (0.770-1.169) & 0.393 & 0.839 & 1.023 (0.822-1.272) & 6 \\
\hline
& Pooled & & 0.402 & & 0.277 & 0.928 (0.810-1.062) & & 0.228 & 0.896 (0.749-1.072) & & 0.721 & 0.966 (0.798-1.169) \\
\hline
rs12631031 & Yuxi & A/G & 0.299 & 0.303 & 0.814 & 1.022 (0.852-1.226) & 0.314 & 0.522 & 1.074 (0.863-1.336) & 0.291 & 0.761 & 0.965 (0.765-1.217) & 5 \\
\hline
& Pooled & & 0.267 & & 0.019 & 1.189 (1.029-1.381) & & 0.020 & 1.251 (1.036-1.510) & & 0.252 & 1.126 (0.919-1.380) \\
\hline
rs7653061 & Yuxi & G/T & 0.484 & 0.467 & 0.444 & 0.937 (0.793-1.107) & 0.473 & 0.678 & 0.958 (0.783-1.173) & 0.461 & 0.400 & 0.913 (0.739-1.129) & 5 \\
\hline
& Pooled & & 0.442 & & 0.121 & 1.110 (0.973-1.266) & & 0.153 & 1.135 (0.954-1.351) & & 0.405 & 1.082 (0.899-1.302) \\
\hline
rs10916832 & Yuxi & C/T & 0.342 & 0.349 & 0.750 & 1.029 (0.862-1.230) & 0.362 & 0.422 & 1.091 (0.882-1.350) & 0.333 & 0.734 & 0.962 (0.767-1.205) & 5 \\
\hline
& Pooled & & 0.34 & & 0.560 & 1.042 (0.908-1.196) & & 0.281 & 1.104 (0.922-1.323) & & 0.785 & 0.973 (0.800-1.184) \\
\hline
rs10916840 & Yuxi & A/G & 0.270 & 0.281 & 0.558 & 1.059 (0.874-1.284) & 0.281 & 0.623 & 1.060 (0.840-1.337) & 0.281 & 0.645 & 1.058 (0.831-1.348) & 4 \\
\hline
& Pooled & & 0.265 & & 0.301 & 1.082 (0.932-1.256) & & 0.431 & 1.083 (0.888-1.319) & & 0.465 & 1.081 (0.877-1.333) \\
\hline
rs1043424 & Yuxi & C/A & 0.363 & 0.357 & 0.783 & 0.976 (0.818-1.164) & 0.362 & 0.961 & 0.995 (0.805-1.230) & 0.352 & 0.677 & 0.954 (0.763-1.192) & 7 \\
\hline
& Pooled & & 0.375 & & 0.279 & 0.927 (0.809-1.063) & & 0.543 & 0.946 (0.789-1.133) & & 0.319 & 0.907 (0.747-1.100) \\
\hline
rs650616 & Yuxi & A/G & 0.437 & 0.468 & 0.149 & 1.133 (0.956-1.344) & 0.457 & 0.427 & 1.087 (0.885-1.333) & 0.480 & 0.112 & 1.189 (0.960-1.473) & 5 \\
\hline
rs3738140 & Yuxi & A/G & 0.067 & 0.058 & 0.380 & 0.856 (0.605-1.211) & 0.052 & 0.225 & 0.763 (0.491-1.183) & 0.065 & 0.864 & 0.963 (0.629-1.476) & 5 \\
\hline
rs4704 & Yuxi & T/C & 0.372 & 0.388 & 0.455 & 1.069 (0.898-1.273) & 0.393 & 0.418 & 1.090 (0.885-1.344) & 0.382 & 0.700 & 1.044 (0.838-1.302) & 4 \\
\hline
& Pooled & & 0.375 & & 0.449 & 1.054 (0.921-1.206) & & 0.426 & 1.075 (0.900-1.284) & & 0.766 & 1.029 (0.851-1.245) \\
\hline
\end{tabular}}
\end{table}
|
PMC5120299_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Study} & \textbf{Outcome} & \textbf{Relative Risk/Incident Density Ratio (95\% CI)} \\
\hline
Luby, Agboatwalla et al 2004 [50] & Diarrhoea \\
\hline
RCT & Mean Incidence \\
\hline
Quality Score 6a & Antibiotic Soap & 0.50 (0.36, 0.63) \\
\hline
& Plain Soap & 0.47 (0.35, 0.59) \\
\hline
Shahid, Greenough et al 1996 [43] & Diarrhoea \\
\hline
CBA & Age groups \\
\hline
Quality Score 1b & 0 – 11 mths & 0.39 (0.29, 0.54) \\
\hline
& 12–23 mths & 0.53 (0.37, 0.77) \\
\hline
& 24–59 mths & 0.44 (0.34, 0.59) \\
\hline
& 6 – 9 yrs & 0.27 (0.19, 0.37) \\
\hline
& 10 – 14 yrs & 0.28 (0.16, 0.49) \\
\hline
& Over 15 yrs & 0.38 (0.30, 0.49) \\
\hline
& All & 0.38 (0.33, 0.43) \\
\hline
Wilson, Chandler et al 1991 [51] & Diarrhoea \\
\hline
CBA & Children $<$11yrs & 0.21 (0.08, 0.53)c \\
\hline
Quality Score 3b & Skin/Eye Disease \\
\hline
& Children $<$11yrs & 2.54d \\
\hline
Han, Hlaing et al 1988, 1989 [36] & Ascaris \\
\hline
RCT & Children 36–59mths & 1.0d \\
\hline
Quality Score 4a & Diarrhoea \\
\hline
& $<$2yrs & 0.69 (0.48, 1.01)e \\
\hline
& $\geq$ 2yrs & 0.67 (0.45, 0.98)e \\
\hline
& All children $<$5yrs & 0.70 (0.54, 0.92)f \\
\hline
& Dysentery \\
\hline
& $<$2yrs & 0.59 (0.22, 1.55) \\
\hline
& $\geq$ 2yrs & 1.21 (0.52, 2.80) \\
\hline
& All children $<$5yrs & 0.93 (0.39, 2.23) \\
\hline
\end{tabular}}
\end{table}
|
PMC2397399_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Strabisme} & \textbf{Effectif} & \textbf{Pourcentage} \\
\hline
Pr$\acute{e}$sent & 102 & 0,5 \\
\hline
Absent & 20509 & 99,66 \\
\hline
Total & 20579 & 100 \\
\hline
\end{tabular}}
\end{table}
|
PMC4725652_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Covariate} & \textbf{Univariate p-value} & \textbf{Overall Survival Multivariate p-value} & \textbf{Multivariate HR (CI 95\%)} \\
\hline
\\
\hline
\\
\hline
\multicolumn{4}{|l|}{IPSS-R} \\
\hline
(Very poor/Poor/Intermediate vs. other) & $<$0.001 & $<$0.001 & 3.50 (1.76-6.96) \\
\hline
\multicolumn{4}{|l|}{AGE} \\
\hline
(Years) & 0.047 & 0.035 & 1.04 (1.01-1.07) \\
\hline
\multicolumn{4}{|l|}{PS (ECOG)} \\
\hline
(0-4) & 0.013 & 0.006 & 1.61 (1.15-2.25) \\
\hline
\multicolumn{4}{|l|}{MYELOFIBROSIS GRADE} \\
\hline
(MF-0/1 vs. MF-2/3) & $<$0.001 & 0.002 & 3.21 (1.53-6.74) \\
\hline
\multicolumn{4}{|l|}{Bejar’s Gene Score for MDS} \\
\hline
(High risk vs. other) & 0.019 & 0.079 & 1.75 (0.94-3.25) \\
\hline
\multicolumn{4}{|l|}{COHESIN COMPLEX MUTATIONS} \\
\hline
(Any variation) & $<$0.001 & 0.115 & 2.09 (0.84-5.20) \\
\hline
\end{tabular}}
\end{table}
|
PMC5058695_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Species} & \textbf{Dose, kJ/m2} & \textbf{Individuals irradiated, n} & \textbf{Total eggs, n} & \textbf{Total eggs hatched, n} & \textbf{Hatchability} \\
\hline
H. dujardini & 0 & 38 & 2655 & 2199 & 0.83 \\
\hline
& 2.5 & 39 & 0 & 0 & n/a \\
\hline
& 5.0 & 38 & 0 & 0 & n/a \\
\hline
& 10.0 & 40 & 0 & 0 & n/a \\
\hline
& 20.0 & 40 & 0 & 0 & n/a \\
\hline
R. varieornatus & 0 & 39 & 529 & 465 & 0.88 \\
\hline
& 2.5 & 37 & 162 & 145 & 0.90 \\
\hline
& 5.0 & 38 & 0 & 0 & n/a \\
\hline
& 10.0 & 40 & 0 & 0 & n/a \\
\hline
& 20.0 & 40 & 0 & 0 & n/a \\
\hline
R. varieornatus (anh.) & 0 & 41 & 819 & 689 & 0.84 \\
\hline
& 2.5 & 40 & 211 & 161 & 0.76 \\
\hline
& 5.0 & 41 & 101 & 81 & 0.80 \\
\hline
& 10.0 & 40 & 36 & 32 & 0.89 \\
\hline
& 20.0 & 19 & 20 & 16 & 0.80 \\
\hline
\end{tabular}}
\end{table}
|
PMC3675078_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{No of cases among childless men (vs fathers)} & \textbf{OR (95\% CI)} \\
\hline
Hyperglycaemia* & 88 (335) & 1.59 (1.21 to 2.08) \\
\hline
Hypo-HDL cholesterolaemia† & 102 (670) & 0.78 (0.60 to 1.01) \\
\hline
Hyperlipidaemia‡ & 97 (515) & 1.04 (0.80 to 1.34) \\
\hline
Waist circumference $>$102 cm & 54 (270) & 1.11 (0.81 to 1.53) \\
\hline
Hypertension$\S$ & 222 (1160) & 1.13 (0.88 to 1.45) \\
\hline
\end{tabular}}
\end{table}
|
PMC6104745_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Obstetric danger sign} & \textbf{n (\%)} \\
\hline
\multicolumn{2}{|l|}{During Pregnancy} \\
\hline
High fever & 157 (21.6) \\
\hline
Severe abdominal pain & 107 (14.7) \\
\hline
Excessive vaginal bleeding & 79 (10.1) \\
\hline
Fits during pregnancy & 70 (9.6) \\
\hline
Severe headache & 61 (8.4) \\
\hline
Swollen hands/face & 22 (3.0) \\
\hline
Loss of consciousness & 15 (2.1) \\
\hline
Blurred vision & 6 (0.8) \\
\hline
Knowledge of at least one signKnowledge of at least one sign & 389 (53.7) \\
\hline
\multicolumn{2}{|l|}{During Childbirth} \\
\hline
Excessive vaginal bleeding & 165 (22.7) \\
\hline
Fits & 101(13.9) \\
\hline
Retained placenta & 65 (9.0) \\
\hline
High fever & 42 (5.8) \\
\hline
Prolonged labour & 35 (4.8) \\
\hline
Severe headache & 29 (4.0) \\
\hline
Loss of consciousness & 13 (1.8) \\
\hline
Knowledge of at least one sign & 318 (43.9) \\
\hline
\multicolumn{2}{|l|}{During postpartum} \\
\hline
Excessive vaginal bleeding & 129 (17.8) \\
\hline
High fever & 52 (7.2) \\
\hline
Fits & 37 (5.1) \\
\hline
Loss of consciousness & 10 (1.4) \\
\hline
Foul smelling discharge & 8 (1.1) \\
\hline
Severe headache & 6 (0.8) \\
\hline
Knowledge at least one sign & 251 (34.6) \\
\hline
\end{tabular}}
\end{table}
|
PMC4423869_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{C1} & \textbf{C2} & \textbf{C3} & \textbf{C4} & \textbf{C5} & \textbf{C6} \\
\hline
Overall (n = 41) & 0 & 19 & 7 & 10 & 0 & 5 \\
\hline
GSV* (n = 34) & 0 & 18 & 6 & 8 & 0 & 2 \\
\hline
SSV** (n = 7) & 0 & 1 & 1 & 2 & 0 & 3 \\
\hline
\end{tabular}}
\end{table}
|
PMC5829688_table_8
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Accession no} & \textbf{Symbol} & \textbf{Gene Name} & \textbf{Reference} \\
\hline
\multicolumn{4}{|l|}{Chemokines and receptors} \\
\hline
[genebank:NM_002983] & CCL3 & Chemokine, CC motif, Ligand 3 $\pi$ & [25] \\
\hline
[genebank:NM_002984] & CCL4 & Chemokine, CC motif, ligand 4 $\pi$ & [25] \\
\hline
[genebank:NM_005408] & CCL13 & Chemokine, CC motif, ligand 13 & [68] \\
\hline
[genebank:NM_032964] & CCL15 & Chemokine, CC motif, ligand 15 & [69] \\
\hline
[genebank:NM_006274] & CCL19 & Chemokine, CC motif, ligand 19 & -1748* \\
\hline
[genebank:NM_002990] & CCL22 & Chemokine, CC motif, ligand 22 $\pi$ & [70] \\
\hline
[genebank:NM_001511] & CXCL1 & Chemokine CC motif, Ligand 1 $\pi$ & [25] \\
\hline
[genebank:NM_002089] & CXCL2 & Chemokine, CXC motif, ligand 2 $\pi$ & [25] \\
\hline
[genebank:NM_000584] & CXCL8 & Chemokine, CXC motif, ligand 8 $\pi$ & [25] \\
\hline
[genebank:NM_001565] & CXCL10 & Chemokine, CXC motif, ligand 10 & [25] \\
\hline
[genebank:NM_005408] & CXCL13 & Chemokine, CXC motif, ligand 13 & -1593* \\
\hline
[genebank:U28934] & CCR2 & Chemokine, CC motif, receptor 2 & -1543* \\
\hline
[genebank:NM_003467] & CXCR4 & Chemokine, CXC motif, receptor 4 $\pi$ & [71] \\
\hline
\multicolumn{4}{|l|}{Cytokines and Receptors} \\
\hline
[genebank:NM_000594] & TNF-$\alpha$ & Tumour Necrosis Factor $\alpha$ $\pi$ & [25] \\
\hline
[genebank:NM_000576] & IL1-$\beta$ & Interleukin 1 B $\pi$ & [25] \\
\hline
[genebank:NM_000577] & IL1-RN & Interleukin 1 receptor antagonist $\pi$ & [25] \\
\hline
[genebank:NM_005746] & PBEF & Pre B cell colony stimulating factor 1 $\pi$ & -533*, -479* \\
\hline
[genebank:NM_001250] & TNFRSF5 & TNF receptor superfamily, member 5 & [72] \\
\hline
[genebank:NM_001561] & TNFRSF9 & TNF receptor superfamily member 9 & [73] \\
\hline
[genebank:NM_005534] & IFNGR2 & Interferon, gamma receptor 2 & -317, -220*, -144, -134* \\
\hline
\multicolumn{4}{|l|}{Stress} \\
\hline
[genebank:NM_000636] & SOD2 & Superoxide dismutase 2 $\pi$p & [25] \\
\hline
[genebank:NM_000963] & COX2 & Cycloxygenase 2 $\pi$ & [25] \\
\hline
[genebank:NM_006427] & TXNIP & Thioredoxin interacting protein $\pi$ & -618 \\
\hline
\multicolumn{4}{|l|}{Apoptosis} \\
\hline
[genebank:NM_015675] & GADD45 $\beta$ & Growth arrest and DNA damage inducible gene GADD45, B $\pi$ & [74] \\
\hline
[genebank:NM_005879] & TRIP & Traf interacting protein & -1736 \\
\hline
[genebank:NM_006290] & TNFAIP3 & Tumour Necrosis factor $\alpha$ induced protein 3 $\pi$ & [25] \\
\hline
[genebank:NM_001165] & cIAP2 & Cellular inhibitor of apoptosis 2 $\pi$ & [75] \\
\hline
\multicolumn{4}{|l|}{Transcription} \\
\hline
[genebank:NM_020529] & I$\kappa$B-$\alpha$ & Inhibitor of $\kappa$light chain gene enhancer in B cells; $\alpha$ $\pi$ & [25] \\
\hline
[genebank:NM_003998] & NF$\kappa$B1 & Nuclear factor of $\kappa$B, subunit 1 $\pi$ & [25] \\
\hline
[genebank:NM_002908] & C-REL & V-rel avain reticuloendotheliosis viral oncogene homolog; rel $\pi$ & [25] \\
\hline
[genebank:NM_005375] & C-MYB & V-MYB avian myeloblastosis viral oncogene homolog $\pi$ & [25] \\
\hline
[genebank:NM_004364] & CEBP$\alpha$ & CAAT/enhancer binding protein $\alpha$ & [25] \\
\hline
[genebank:U96131] & TRIP13 & Thyroid hormone interactor 13 & -1611, -1601*, -1600* -1464* \\
\hline
[genebank:NM_002129] & HMGB2 & High mobility group box 2 & -1531, -1520, -1087 \\
\hline
\multicolumn{4}{|l|}{Cell Cycle/Differentiation} \\
\hline
[genebank:NM_006763] & BTG2 & B-cell translocation gene 2 $\pi$ & [76] \\
\hline
[genebank:NM_002166] & ID2 & Inhibitor of DNA binding 2 $\pi$ & -571*, -174 \\
\hline
[genebank:X54941] & CKS1B & CDC28 protein kinase 1B & -1416, -1406* -717, -647, -637*, -646 -636* \\
\hline
[genebank:NM_004701] & CCNB2 & Cyclin B2 & -1387 \\
\hline
\multicolumn{4}{|l|}{Growth} \\
\hline
[genebank:NM_000598] & IGFBP3 & Insulin-like growth-factor binding protein 3 $\pi$ & -1729 \\
\hline
\multicolumn{4}{|l|}{Miscellaneous} \\
\hline
[genebank:NM_000674] & ADORA1 & Adenosine A1 receptor & [25] \\
\hline
[genebank:NM_000201] & ICAM1 & Intracellular adhesion molecule 1 $\pi$ & [25] \\
\hline
[genebank:NM_002421] & MMP1 & Matrix metalloproteinase 1 & [25] \\
\hline
[genebank:X13895] & SAA3P & Serum amyloid A3 pseudogene & -1790* \\
\hline
[genebank:NM_002291] & LAM$\beta$1 & Laminin, $\beta$ 1 & -263, -253 \\
\hline
[genebank:NM_004119] & FLT3 & FMS related tyrosine kinase 3 & -295, -285* \\
\hline
[genebank:NM_001365] & DLG4 & Discs, large homolog 4 & -1425, -1415*, -544* \\
\hline
[genebank:M22001] & F13A1 & Coagulation factor X111, A1 polypeptide & -404, -72* \\
\hline
\end{tabular}}
\end{table}
|
PMC1781469_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Grade group} & \textbf{Math anxiety level} & \multicolumn{3}{|l|}{\textbf{Mean RT (ms)}} & \multicolumn{3}{|l|}{\textbf{Accuracy (\%)}} \\
\hline
& & \textbf{C1} & \textbf{C2} & \textbf{C3} & \textbf{C1} & \textbf{C2} & \textbf{C3} \\
\hline
Grade four group & High anxiety & 10789 (3441) & 9608 (2745) & 5650 (2069) & 61.41 (12.63) & 92.10 (6.69) & 96.85 (3.33) \\
\hline
& Low anxiety & 11599 (3978) & 8107 (2400) & 5060 (1753) & 61.97 (16.23) & 94.39 (5.44) & 98.45 (2.60) \\
\hline
Grade six group & High anxiety & 9688 (4594) & 7096 (2411) & 4489 (1709) & 61.24 (16.45) & 94.17 (6.61) & 96.88 (3.82) \\
\hline
& Low anxiety & 8870 (3637) & 5816 (2222) & 3437 (1313) & 75.75 (15.36) & 97.25 (3.60) & 98.81 (2.17) \\
\hline
Adult group & High anxiety & 6071 (1131) & 3813 (768) & 2583 (557) & 83.93 (10.84) & 96.43 (4.19) & 98.22 (1.9) \\
\hline
& Low anxiety & 6100 (1586) & 3935 (754) & 2334 (335) & 85.03 (12.21) & 96.60 (3.03) & 98.30 (2.91) \\
\hline
\end{tabular}}
\end{table}
|
PMC5067409_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Layer} & \textbf{Vlo} & \textbf{ny} & \textbf{R2} & \textbf{Jmo} & \textbf{ny} & \textbf{R2} \\
\hline
15 & 88.62 $\pm$ 8.20z & 5 & 0.76 & 175.42 $\pm$ 13.17 & 5 & 0.71 \\
\hline
13 & 81.72 $\pm$ 5.74 & 5 & 0.83 & 123.97 $\pm$ 9.77 & 5 & 0.78 \\
\hline
11 & 77.93 $\pm$ 6.24 & 5 & 0.70 & 119.64 $\pm$ 9.87 & 5 & 0.85 \\
\hline
9 & 71.25 $\pm$ 5.60 & 5 & 0.80 & 107.64 $\pm$ 11.84 & 5 & 0.75 \\
\hline
7 & 68.56 $\pm$ 6.88 & 5 & 0.69 & 88.63 $\pm$ 12.47 & 5 & 0.69 \\
\hline
5 & 56.08 $\pm$ 7.09 & 5 & 0.73 & 72.62 $\pm$ 14.08 & 5 & 0.73 \\
\hline
3 & 32.82 $\pm$ 7.70 & 5 & 0.66 & 67.49 $\pm$ 14.66 & 5 & 0.67 \\
\hline
1 & 20.31 $\pm$ 2.57 & 5 & 0.88 & 50.83 $\pm$ 10.69 & 5 & 0.73 \\
\hline
\end{tabular}}
\end{table}
|
PMC5016622_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{7}{|l|}{\textbf{UCP2 Genotype}} \\
\hline
& \textbf{n} & \textbf{AA} & \textbf{n} & \textbf{GA} & \textbf{n} & \textbf{GG} & \textbf{p} \\
\hline
Gender (M/F) & 140 & 102/38(72.9\%M) & 410 & 309/101(75.4\%M) & 351 & 292/59 (83.2\%M) & 0.009 \\
\hline
Age (years)* & 140 & 61.5 $\pm$ 0.94 & 410 & 62.0 $\pm$ 0.49 & 350 & 62.7 $\pm$ 057 & 0.404 \\
\hline
BMI* (kgm-2) & 92 & 27.2 $\pm$ 0.51 & 285 & 26.9 $\pm$ 0.25 & 239 & 26.4 $\pm$ 0.25 & 0.174 \\
\hline
LVEF & 113 & 47.2 $\pm$ 1.00 & 348 & 48.0 $\pm$ 0.64 & 288 & 47.9 $\pm$ 0.72 & 0.822 \\
\hline
Predischarge Mean arterial pressure (mmHg) & 133 & 82.9 $\pm$ 0.87 & 397 & 83.2 $\pm$ 0.55 & 341 & 84.6 $\pm$ 0.61 & 0.145 \\
\hline
Predischarge Systolic Blood pressure (mmHg) & 133 & 117 $\pm$ 1.28 & 397 & 116 $\pm$ 0.81 & 341 & 118 $\pm$ 0.90 & 0.163 \\
\hline
Predischarge Diastolic Blood pressure (mmHg)(mmHg) & 133 & 65.9 $\pm$ 0.82 & 397 & 66.8 $\pm$ 0.54 & 341 & 67.8 $\pm$ 0.57 & 0.176 \\
\hline
\multicolumn{8}{|l|}{History} \\
\hline
Previous myocardial infarction* & 127 & 24(18.9\%) & 389 & 72 (18.5\%) & 334 & 58 (17.4\%) & 0.896 \\
\hline
hypertension * & 129 & 47(36.4\%) & 400 & 157 (39.3\%) & 342 & 131 (38.3\%) & 0.847 \\
\hline
Type 2 Diabetes* & 139 & 22(15.8\%) & 409 & 48(11.7\%) & 349 & 38 (10.9\%) & 0.308 \\
\hline
Predischarge Atrial Fibrillation* Fibrillation* & 112 & 12(10.7\%) & 346 & 35 (10.1\%) & 297 & 47 (15.8\%) & 0.076 \\
\hline
Predischarge Ventricular Fibrillation* Fibrillation* & 113 & 11(9.7\%) & 355 & 40 11.3\%) & 300 & 21 (7.0\%) & 0.173 \\
\hline
\multicolumn{8}{|l|}{Laboratory Data} \\
\hline
Total Cholesterol* (mmol/l) & 130 & 5.94 $\pm$ 0.10 & 376 & 5.95 $\pm$ 0.065 & 330 & 5.81 $\pm$ 0.068 & 0.325 \\
\hline
HDL Cholesterol* (mmol/l) & 129 & 1.16 $\pm$ 0.026 & 371 & 1.16 $\pm$ 0.017 & 325 & 1.15 $\pm$ 0.018 & 0.913 \\
\hline
LDL Cholesterol* (mmol/l) & 97 & 3.96 $\pm$ 0.10 & 299 & 3.98 $\pm$ 0.058 & 268 & 3.83 $\pm$ 0.069 & 0.225 \\
\hline
Triglycerides* (mmol/l) & 130 & 2.02 $\pm$ 0.11 & 376 & 2.08 $\pm$ 0.096 & 330 & 2.01 $\pm$ 0.069 & 0.791 \\
\hline
Plasma Creatinine† ($\mu$mol/l) & 136 & 83 (79–87) & 405 & 85 (82–87) & 347 & 85 (83–87) & 0.600 \\
\hline
Creatinine Clearance* (ml/s) & 99 & 1.28 $\pm$ 0.047 & 308 & 1.28 $\pm$ 0.023 & 267 & 1.32 $\pm$ 0.028 & 0.546 \\
\hline
Peak Creatine kinase† (units/l) & 105 & 1440(1250–1660) & 327 & 1610(1480–1740) & 269 & 1640(1510–1680) & 0.304 \\
\hline
Plasma Glucose (mmol/l) & 137 & 8.55 $\pm$ 0.27 & 404 & 8.64 $\pm$ 0.15 & 344 & 8.55 $\pm$ 0.16 & 0.912 \\
\hline
Glycated Hemoglobin \% & 105 & 6.07 $\pm$ 0.11 & 324 & 6.06 $\pm$ 0.06 & 274 & 6.03 $\pm$ 0.06 & 0.905 \\
\hline
\multicolumn{8}{|l|}{Discharge Medications} \\
\hline
ACE inhibitor * & 122 & 36(29.5\%) & 374 & 121 (32.4\%) & 318 & 109 (34.3\%) & 0.624 \\
\hline
$\beta$-blocker * & 122 & 78(63.9\%) & 374 & 232 (62.0\%) & 318 & 176 (55.3\%) & 0.119 \\
\hline
\multicolumn{8}{|l|}{Neurohormonal Data} \\
\hline
ANP (pmol/l)‡ & 138 & 26.8(24.4–29.4) & 403 & 28.5(27.0–30.0) & 346 & 28.8(27.1–30.6) & 0.406 \\
\hline
BNP (pmol/l)‡ & 138 & 18.2(16.4–20.2) & 404 & 19.8(18.7–21.0) & 346 & 19.9(18.8–21.1) & 0.290 \\
\hline
NTproBNP (pmol/l)‡ & 137 & 98.6(87.0–112) & 399 & 112(104–121) & 344 & 111(103–121) & 0.200 \\
\hline
Endothelin-1 (pmol/l)‡ & 137 & 1.64(1.52–1.77) & 398 & 1.80(1.73–1.88) & 340 & 1.76(1.167–1.81) & 0.110 \\
\hline
\end{tabular}}
\end{table}
|
PMC2702310_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{No} & \textbf{Age} & \textbf{Sex} & \textbf{Surgery} & \textbf{Emergency} & \textbf{Initial symptoms/findings} & \textbf{Duration between Surgery} & \multicolumn{5}{|l|}{\textbf{Patient state at the onset of NOMI}} & \textbf{Result} \\
\hline
& & & & & & \textbf{and NOMI(days)} & \textbf{NOE $>$ 0.10 $\mu$g/kg/min} & \textbf{LOS} & \textbf{Sepsis} & \textbf{HD} & \textbf{Sedation} \\
\hline
1 & 83 & Male & TAR & No & Hyperlactatemia & 13 & Yes & No & No & Yes & Yes & Death \\
\hline
2 & 81 & Male & OPCABG & No & Hematochezia & 64 & No & No & Yes & Yes & Yes & Death \\
\hline
3 & 67 & Male & OPCABG & No & Abdominal pain & 13 & No & No & No & No & No & Survival \\
\hline
4 & 66 & Male & OPCABG & No & Abdominal pain & 34 & No & No & Yes & No & No & Survival \\
\hline
5 & 77 & Female & AAR & Yes & Hyperlactatemia & 17 & Yes & Yes & No & Yes & Yes & Death \\
\hline
6 & 81 & Male & CABG & No & Hyperlactatemia & 30 & Yes & Yes & No & No & No & Death \\
\hline
7 & 86 & Male & OPCABG & Yes & Hyperlactetamia & 8 & Yes & Yes & No & Yes & Yes & Death \\
\hline
8 & 69 & Female & OPCABG & No & Hyperlactetamia & 11 & Yes & No & No & Yes & Yes & Death \\
\hline
9 & 67 & Female & CABG & No & Hyperlactatemia & 2 & Yes & No & No & Yes & Yes & Death \\
\hline
10 & 76 & Female & MVP, TAP & No & Vomiting & 15 & No & No & No & No & No & Survival \\
\hline
11 & 79 & Male & CABG, MVR & No & Hypotension & 15 & Yes & Yes & Yes & Yes & Yes & Death \\
\hline
12 & 64 & Male & CABG & Yes & Hyperlactatemia & 5 & No & Yes & No & Yes & Yes & Death \\
\hline
\end{tabular}}
\end{table}
|
PMC6240249_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{BUILD Period} & \textbf{SEM/YR} & \textbf{BTP Trainees} & \textbf{Comment} \\
\hline
1 & SR 15 & Build a Bridge to Success (BBS) Math Preparation SURF – Attendance & Establishing a strong foundation Math 106 – Algebra (if needed) BBS – Career engagement and exploration, the Scientific Method, Group Research Experience \\
\hline
& FA 15 & Quantitative Reasoning Laboratory Intro to a Research University (IRU) STEM LLC, BUILD UP, Leadership Series UGRS/posters (Microbiome Project) & IRU – study skills, time management, academic integrity, communication skills, diversity Pre-Calculus and English 100/110 Standard Classesa \\
\hline
& SP 16 & STEM LLC, BUILD UP, Leadership Series & Standard Classesa \\
\hline
2 & SR 16 & Bioanalytical Research Training (BRT) EHS 115 – Medical Terminologyb SURF, (Bridge Repeat)d & Developing technical laboratory skills in context of authentic question \\
\hline
& FA 16 & Intro to Discovery (ID) UGRS/Posters (BRT) STEM LLCc, BUILD UP, Leadership Series & ID – Finding research opportunities, Applications/Resumes/Elevator Pitches Standard Classesa \\
\hline
& SP 17 & STEM LLCc, BUILD UP, Leadership Series & Standard Classesa \\
\hline
3 & SR 17 & Phage Hunters, REU, Internships, BGR GRE Preparation, SURF, (Bridge Repeat)d & Engaging in authentic research and developing laboratory, scientific communication, and research skills \\
\hline
& FA 17 & Intro to Post-Bac (IPB) UGRS/Posters (Phage Hunters) STEM LLCc, BUILD UP, Leadership Series & IPB – Careers/Proposal Writing Standard Classesa \\
\hline
& SP 18 & Ethics and Integrity in Scientific Research URCAD/Oral Presentations STEM LLCc, BUILD UP, Leadership Series & Standard Classesa \\
\hline
4 & SR 18 & REU, Internships, BGR GRE Preparation Course Biomedical Case Studies Course (Bridge Repeat)d & Implementation of Skills and Competencies \\
\hline
& FA 18 & UGRS/Posters STEM LLCc, BUILD UP, Leadership Series & Standard Classesa \\
\hline
& SP 19 & URCAD/Oral Presentations STEM LLCc, BUILD UP, Leadership Series & Standard Classesa \\
\hline
\end{tabular}}
\end{table}
|
PMC5773890_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{6}{|l|}{\textbf{Quintile of the CHEI}} \\
\hline
\textbf{Selected Food Groups} & \textbf{Q1 (n = 2494)} & \textbf{Q2 (n = 2495)} & \textbf{Q3 (n = 2495)} & \textbf{Q4 (n = 2495)} & \textbf{Q5 (n = 2494)} & \textbf{P for Trend 1} \\
\hline
CHEI score & 38.02 & 46.89 & 52.45 & 58.21 & 68.01 \\
\hline
Whole grains (g/1000 kcal per day) & 7.54 & 9.69 & 12.58 & 13.21 & 16.53 & $<$0.0001 \\
\hline
Refine grains (g/1000 kcal per day) & 208.23 & 209.50 & 203.13 & 197.06 & 179.48 & $<$0.0001 \\
\hline
Dairy products (g/1000 kcal per day) & 4.05 & 6.89 & 9.58 & 18.08 & 41.11 & $<$0.0001 \\
\hline
Seed and nuts (g/1000 kcal per day) & 0.86 & 1.20 & 2.20 & 3.05 & 5.54 & $<$0.0001 \\
\hline
Fruits (g/1000 kcal per day) & 7.81 & 15.08 & 27.30 & 44.75 & 79.07 & $<$0.0001 \\
\hline
Vegetables (g/1000 kcal per day) & 145.48 & 154.22 & 156.78 & 159.96 & 167.43 & $<$0.0001 \\
\hline
Fish and seafood (g/1000 kcal per day) & 7.70 & 9.85 & 11.58 & 14.64 & 21.98 & $<$0.0001 \\
\hline
Red meat (g/1000 kcal per day) & 39.69 & 41.88 & 39.41 & 40.71 & 38.22 & 0.039 \\
\hline
\end{tabular}}
\end{table}
|
PMC5852690_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Primer No.} & \textbf{Primer Sequence (59-39)} & \textbf{Strain designation} & \textbf{Mutation} \\
\hline
1 & ATT CCC GGG TTT GAC TCT ATC TAG TGT CAG & BSU 689 & D(G123-L138) \\
\hline
2 & ATA CCC GGG GCG ACA GTT TAT GAC CCA C \\
\hline
3 & GCC GCG CAT ATG TGT GAT AAG TCA GCAAAC CCC A \\
\hline
4 & GCC GCG CTC GAG CTT CAA CTG TTG ATA GAG CAC TTC C \\
\hline
5 & GCG ACA CTT TAT GAC CCA GCT ACC TGG ACG GAT CCC & BSU 716 & H142A \\
\hline
6 & GGG ATC CGT CCA GGT AGC TGG GTC ATA AAG TGT CGC \\
\hline
7 & GTG ACG CAA GCC ACG GCA TTT TCT TAT CTG & BSU 718 & H142-206A \\
\hline
8 & CAG ATA AGA AAA TGC CGT GGC TTG CGT CAC \\
\hline
9 & CAA TCA GGT GCA GGC ATT GCT TCC TTT GAA CCG & BSU 778 & H142-206-66A \\
\hline
10 & CGG TTC AAA GGA AGC AAT GCC TGC ACC TGA TTG \\
\hline
11 & ATT CCC GGG ATA CCT GGA CGG ATC CCG TTT TAG & BSU 691 & DPH(140-142)-ARD \\
\hline
12 & ATA CCC GGG CAT AAA GTG TCG CAG GGT CAA TGC \\
\hline
13 & ATCAGGTGCAGGCATTAATTCC & BSU 702 & H66N \\
\hline
14 & GTG GTG CTC GAG CTT CAA CTG TTG ATA GAG CAC TTC C \\
\hline
15 & ACG GTT CAA AGG AAT TAA TGC C \\
\hline
16 & GAT ATA CAT ATG TGT GAT AAG TCA GCA AAC CCC A \\
\hline
11 & ATT CCC GGG ATA CCT GGA CGG ATC CCG TTT TAG & BSU 704 & DPH(140-142)- ARD+H66N \\
\hline
12 & ATA CCC GGG CAT AAA GTG TCG CAG GGT CAA TGC \\
\hline
17 & AAA GTA AAG ACA TTA AGT GCA CTT GAA GCT GCT CCA & BSU777 & P279A \\
\hline
18 & TGG AGC AGC TTC AAG TGC ACT TAA TGT CTT TAC TTT \\
\hline
19 & GCT AAA GTA AAG ACA TTA AGT GCA CTT GAA GCT GCT CC & BSU 751 & H264A \\
\hline
20 & GG AGC AGC TTC AAG TGC ACT TAA TGT CTT TAC TTT AGC \\
\hline
\end{tabular}}
\end{table}
|
PMC3691195_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Total number of patients} & \textbf{CDI1 n (\%) 65 (3.1)} & \textbf{p value2} \\
\hline
\\
\hline
\\
\hline
\multicolumn{4}{|l|}{Type of malignancy} \\
\hline
Acute myeloid leukaemia no remission (C92)3 & 154 & 11 (7.1) & .003 \\
\hline
Acute myeloid leukaemia in remission3 & 16 & 1 (6.3) & .469 \\
\hline
Acute lymphoblastic leukaemia no remission (C91.0)3 & 66 & 9 (13.6) & $<$0.001 \\
\hline
Acute lymphoblastic leukaemia in remission3 & 43 & 3 (7.0) & .141 \\
\hline
\multicolumn{4}{|l|}{Non-Hodgkin’s lymphoma} \\
\hline
Non-Hodgkin’s lymphoma—follicular (C82)3 & 225 & 4 (1.8) & .308 \\
\hline
Non-Hodgkin’s lymphoma—remaining (C83, C84, C85, C86, C88)3 & 762 & 21 (2.8) & .515 \\
\hline
Hodgkin’s lymphoma (C81)3 & 105 & 1 (1.0) & .256 \\
\hline
Multiple myeloma no remission (C90)3 & 463 & 10 (2.2) & .179 \\
\hline
Multiple myeloma in remission4 & 6 & 0 & .660 \\
\hline
Other leukaemia (C92 to C96)3 & 109 & 3 (2.8) & 1.00 \\
\hline
\multicolumn{4}{|l|}{Comorbidities} \\
\hline
Peptic ulcer & 21 & 3 (14.3) & 0.026 \\
\hline
Renal disease & 121 & 8 (6.6) & 0.023 \\
\hline
\multicolumn{4}{|l|}{Other Infections} \\
\hline
Any bacterial infection prior to CDI5 & 670 & 38 (5.7) & $<$0.001 \\
\hline
Sepsis at any time & 256 & 31 (12.1) & $<$0.001 \\
\hline
Bacterial pneumonia at any time & 232 & 16 (6.9) & $<$0.001 \\
\hline
Bacterial infection other than pneumonia at any time & 569 & 46 (8.1) & $<$0.001 \\
\hline
Other severe infection at any time & 33 & 4 (12.1) & 0.018 \\
\hline
\end{tabular}}
\end{table}
|
PMC4912117_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Parameter of interest} & \textbf{No acute kidney injury (n = 362)} & \textbf{Risk class (n = 165)} & \textbf{Injury class (n = 71)} & \textbf{Failure class (n = 80)} & \textbf{Loss or end-stage renal disease (n = 44)} \\
\hline
Mean age (years) $\pm$ SD & 57.89 $\pm$ 18.2 & 59.68 $\pm$ 18.4 & 57.14 $\pm$ 16.7 & 56.51 $\pm$ 21.3 & 63.09 $\pm$ 14.7 \\
\hline
Sex, males (\%) & 213 (58.8\%) & 96 (58.2\%) & 41 (57.7\%) & 41 (51.3\%) & 27 (61.4\%) \\
\hline
Mean APACHE II score $\pm$ SD & 10.68 $\pm$ 6.9 & 14.64 $\pm$ 7.6 & 19.7 $\pm$ 8.2 & 24.34 $\pm$ 8.1 & 16.91 $\pm$ 8 \\
\hline
Mean PDR $\pm$ SD & 16.09 $\pm$ 15.8 & 24.33 $\pm$ 19.2 & 37.13 $\pm$ 23.7 & 49.45 $\pm$ 23.4 & 30.66 $\pm$ 21 \\
\hline
Mean SOFA score $\pm$ SD & 3.39 $\pm$ 2.4 & 5.27 $\pm$ 3.3 & 7.15 $\pm$ 3.7 & 8.95 $\pm$ 3.4 & 5.39 $\pm$ 3.7 \\
\hline
Need for inotropic support & 56 (15.5\%) & 41 (24.8\%) & 28 (39.4\%) & 40 (50\%) & 14 (31.8\%) \\
\hline
Need for renal support & 4 (1.1\%) & 7 (4.2\%) & 19 (26.8\%) & 58 (72.5\%) & 34 (77.3\%) \\
\hline
Need for mechanical ventilation & 66 (18.2\%) & 43 (26.1\%) & 28 (39.4\%) & 32 (40\%) & 15 (34.1\%) \\
\hline
Length of ICU stay, days & 4.53 $\pm$ 5.2 & 5.25 $\pm$ 5.1 & 4.46 $\pm$ 4.8 & 6.44 $\pm$ 6.5 & 5.68 $\pm$ 6.2 \\
\hline
Length of hospital stay, days & 8.55 $\pm$ 7.1 & 9.2 $\pm$ 6.4 & 8.34 $\pm$ 7.1 & 10.76 $\pm$ 11.9 & 9.57 $\pm$ 7.1 \\
\hline
ICU mortality & 27 (7.5\%) & 26 (15.8\%) & 18 (25.4\%) & 31 (38.8\%) & 9 (20.5\%) \\
\hline
\end{tabular}}
\end{table}
|
PMC3504819_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Effect} & \textbf{Pillai(df)} & \textbf{Approximate F(df)} & \textbf{P-value} \\
\hline
Age & 0.99(1) & 48.28 (25,9) & ,0.0001 \\
\hline
Experience & 0.76(1) & 1.17 (25,9) & 0.43 \\
\hline
Age*Experience & 0.87(1) & 2.46(25,9) & 0.08 \\
\hline
\end{tabular}}
\end{table}
|
PMC2702002_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\multicolumn{3}{|l|}{\textbf{Obstetric characteristics}} \\
\hline
\textbf{Gestation in weeks} & \textbf{38 + 6} & \textbf{(37 + 6–39 + 2)} \\
\hline
Primiparous & 6 & (18.8) \\
\hline
Multiparous & 26 & (81.2) \\
\hline
\multicolumn{3}{|l|}{Primary indication for elective caesarean section} \\
\hline
Previous caesarean section & 13 & (40.6) \\
\hline
Breech presentation & 6 & (18.8) \\
\hline
Placenta praevia & 2 & (6.3) \\
\hline
Twin pregnancy & 1 & (3.1) \\
\hline
Previous traumatic delivery & 3 & (9.4) \\
\hline
Medical co-morbidity & 6 & (18.8) \\
\hline
Maternal choice & 1 & (3.1) \\
\hline
\multicolumn{3}{|l|}{Infant} \\
\hline
Live births & 32 & (100) \\
\hline
Birthweight in grams & 3.225 & (2900–3635) \\
\hline
Admission to neonatal unit & 5 & (15.6) \\
\hline
\end{tabular}}
\end{table}
|
PMC5723065_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Variable} & \textbf{Study subjects with UI (n = 1,777)} & \textbf{Control group Aa (n = 8,885)} & \textbf{Control group Bb (n = 8,885)} & \textbf{Control group Cc (n = 8,885)} & \textbf{p-value 1} & \textbf{p-value 2} & \textbf{p-value 3} \\
\hline
Sex & & & & & 1.000 & 1.000 & 1.000 \\
\hline
Female & 1,428 (80.4\%) & 7,140 (80.4\%) & 7,140 (80.3\%) & 7,140 (80.3\%) \\
\hline
Male & 349(19.6\%) & 1,745 (19.6\%) & 1,745 (19.6\%) & 1,745 (19.6\%) \\
\hline
Age, years & & & & & 0.4116 & 0.4635 & 0.4498 \\
\hline
Mean$\pm$STD & 57.93$\pm$14.7 & 57.62$\pm$15.03 & 57.65$\pm$14.97 & 57.64$\pm$14.97 \\
\hline
Median (Range) & 59.54 (21.07,91.11) & 58.96 (17.08, 94.09) & 59.04 (16.84, 93.83) & 59.07 (17.32,94.34) \\
\hline
Mean difference (UI—No UI) & - & 0.3196 & 0.2843 & 0.2932 \\
\hline
Metabolic Syndrome & & & & & - & 1.000 & 1.000 \\
\hline
Yes & 183 (10.3\%) & - & 915(10.3\%) & 915(10.3\%) \\
\hline
No & 1,594 (89.7\%) & - & 7,970(89.7\%) & 7,970(89.7\%) \\
\hline
Upper UTS & & & & & $<$0.0001*+ & $<$0.0001*+ & $<$0.0001*+ \\
\hline
Yes & 334(18.8\%) & 865(9.7\%) & 888(10\%) & 930 (10.5\%) \\
\hline
No & 1,443 (81.2\%) & 8,020 (90.3\%) & 7,997 (90\%) & 7955 (89.5\%) \\
\hline
\end{tabular}}
\end{table}
|
PMC4990176_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{“CIT program number”} & \textbf{Pulse repetition rates (Hz)} \\
\hline
4 & 10.0 \\
\hline
16 & 16.0 \\
\hline
10 & 20.6 \\
\hline
18 & 23.8 \\
\hline
20 & 26.0 \\
\hline
64 & 33.0 \\
\hline
31 & 49.9 \\
\hline
81 & 52.3 \\
\hline
114 & 75.6 \\
\hline
124 & 90.6 \\
\hline
\end{tabular}}
\end{table}
|
PMC6079332_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& \textbf{Provinces} & \textbf{2010} & \textbf{2011} & \textbf{2012} & \textbf{2013} & \textbf{2014} & \textbf{Total} \\
\hline
1 & Baluchestan & 10 & 35 & 20 & 142 & 3 & 210 \\
\hline
2 & South Khorasan & 0 & & 0 & 1 & 1 & 2 \\
\hline
3 & Khorasan Razavi & 0 & 3 & 0 & 1 & 0 & 4 \\
\hline
4 & Hormozgan & 0 & 4 & 0 & 8 & 0 & 12 \\
\hline
5 & Bushehr & 1 & 1 & 1 & 0 & 3 & 6 \\
\hline
6 & Khuzestan & 2 & 3 & 1 & 0 & 0 & 6 \\
\hline
7 & Lorestan & 0 & 2 & 0 & 0 & 0 & 2 \\
\hline
8 & Kermanshah & 0 & 0 & 2 & 0 & 0 & 2 \\
\hline
9 & Hamedan & 0 & 1 & 0 & 0 & 0 & 1 \\
\hline
10 & Kordestan & 0 & 0 & 23 & 0 & 0 & 23 \\
\hline
11 & West Azarbayejan & 0 & 0 & 5 & 0 & 0 & 5 \\
\hline
12 & Ardebil & 0 & 3 & 0 & 0 & 0 & 3 \\
\hline
13 & Zanjan & 0 & 67 & 0 & 0 & 0 & 67 \\
\hline
14 & Qazvin & 0 & 89 & 1 & 5 & 0 & 95 \\
\hline
15 & Markazi & 0 & 11 & 0 & 0 & 0 & 11 \\
\hline
16 & Fars & 0 & 3 & 0 & 8 & 0 & 11 \\
\hline
17 & Kerman & 0 & 3 & 0 & 73 & 0 & 76 \\
\hline
18 & Esfehan & 0 & 12 & 0 & 2 & 0 & 14 \\
\hline
19 & Yazd & 2 & 4 & 0 & 0 & 0 & 6 \\
\hline
20 & Qom & 0 & 138 & 0 & 3 & 0 & 141 \\
\hline
21 & Tehran & 0 & 171 & 0 & 10 & 1 & 182 \\
\hline
22 & Alborz & 0 & 233 & 0 & 2 & 1 & 236 \\
\hline
23 & Semnan & 0 & 16 & 0 & 0 & 0 & 16 \\
\hline
24 & Mazandaran & 0 & 3 & 0 & 0 & 0 & 3 \\
\hline
25 & Golestan & 0 & 157 & 0 & 0 & 2 & 159 \\
\hline
26 & Gilan & 0 & 229 & 0 & 0 & 0 & 229 \\
\hline
& Total & 15 & 1188 & 53 & 257 & 9 & 1522 \\
\hline
\end{tabular}}
\end{table}
|
PMC5062172_table_5
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Conse-} & \textbf{BAC library} & \textbf{EST library} \\
\hline
geno- Reads • SSR-1 & 11.89 & 26.11 \\
\hline
a Bases • SSR-1 (kb) & 7.048 & 18.49 \\
\hline
alle- \% SSR sequence & 0.27\% & 0.06\% \\
\hline
Number of repeats & 9.96 & 5.92 \\
\hline
\end{tabular}}
\end{table}
|
PMC2996956_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{JAMA} & \textbf{HON} & \textbf{DISCERN} \\
\hline
1. Authorship 2. Source attribution 3. Ownership disclosure 4. Currency & 1. Authorship 2. Attribution 3. Privacy 4. Complementarity 5. Transparency 6. Justifiability 7. Financial disclosure 8. Advertising policy & Is the publication reliable? 1. Are the aims clear? 2. Does it achieve its aims? 3. Is it relevant? 4. Is it clear what sources of information were used to compile the publication (other than the author or producer)? 5. Is it clear when the information used or reported in the publication was produced? 6. Is it balanced and unbiased? 7. Does it provide details of additional sources of support and information? 8. Does it refer to areas of uncertainty? How good is the quality of information on treatment choices? 9. Does it describe how each treatment works? 10. Does it describe the benefits of each treatment? 11. Does it describe the risks of each treatment? 12. Does it describe what would happen if no treatment is used? 13. Does it describe how the treatment choices affect overall quality of life? 14. Is it clear that there may be more than one possible treatment choice? 15. Does it provide support for shared decision-making? \\
\hline
\end{tabular}}
\end{table}
|
PMC6158347_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{4}{|l|}{\textbf{Total (N = 60)}} & \multicolumn{4}{|l|}{\textbf{Males (N = 23)}} \\
\hline
& \textbf{NA} & \textbf{\%} & \textbf{Frequency} & \textbf{Individual} & \textbf{NA} & \textbf{\%} & \textbf{Frequency} & \textbf{Individual} \\
\hline
ETH10 & 0 & 0 & - & & 1 & 25 & 0.167 & Keskil, Erel \\
\hline
HEL5 & 0 & 0 & - & & 1 & 25 & 0.083 & Sarial \\
\hline
INRA023 & 2 & 67 & 0.083 & Radzu, Alii & 2 & 67 & 0.083 & Radzu, Alii \\
\hline
INRA063 & 0 & 0 & - & & 1 & 50 & 0.250 & Keskil, Moxsogol, Sarial \\
\hline
CSSM66 & 0 & 0 & - & & 1 & 17 & 0.167 & Erel \\
\hline
ILSTS006 & 0 & 0 & - & & 2 & 67 & 0.250 & Keskil, Moxsogol \\
\hline
TGLA227 & 1 & 14 & 0.083 & Keskil & 1 & 17 & 0.083 & Keskil \\
\hline
TGLA122 & 0 & 0 & - & & 2 & 50 & 0.083 & Moxsogol, Erel \\
\hline
HAUT27 & 0 & 0 & - & & 1 & 14 & 0.083 & Keskil \\
\hline
ETH185 & 0 & 0 & - & & 1 & 25 & 0.167 & Keskil, Moxsogol \\
\hline
TGLA53 & 1 & 11 & 0.083 & Keskil & 1 & 17 & 0.083 & Keskil \\
\hline
SPS115 & 0 & 0 & - & & 1 & 50 & 0.083 & Alii \\
\hline
Average & & 3 & & & & 13 \\
\hline
\end{tabular}}
\end{table}
|
PMC2909159_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Antibodya} & \textbf{Calibratorb} & \multicolumn{3}{|l|}{\textbf{Arrayc}} \\
\hline
& & \textbf{1} & \textbf{2} & \textbf{3} \\
\hline
EGFR \#1 & 1 & 59\% & 60\% & 61\% \\
\hline
& 2 & 58\% & 58\% & 60\% \\
\hline
EGFR \#2 & 1 & 85\% & 85\% & 84\% \\
\hline
& 2 & 85\% & 85\% & 84\% \\
\hline
\end{tabular}}
\end{table}
|
PMC3022873_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{GOBPID} & \textbf{Pvalue} & \textbf{Count} & \textbf{Size} & \textbf{Term} \\
\hline
GO:0045064 & 0.010795911 & 1 & 2 & T-helper 2 cell differentiation \\
\hline
GO:0042097 & 0.010795911 & 1 & 2 & interleukin-4 biosynthesis \\
\hline
GO:0042109 & 0.010795911 & 1 & 2 & tumor necrosis factor-beta biosynthesis \\
\hline
GO:0045624 & 0.016150771 & 1 & 3 & positive regulation of T-helper cell differentiation \\
\hline
GO:0030154 & 0.025370559 & 7 & 537 & cell differentiation \\
\hline
GO:0042092 & 0.02677505 & 1 & 5 & T-helper 2 type immune response \\
\hline
GO:0042093 & 0.02677505 & 1 & 5 & T-helper cell differentiation \\
\hline
GO:0045086 & 0.032044769 & 1 & 6 & positive regulation of interleukin-2 biosynthesis \\
\hline
GO:0045621 & 0.037286403 & 1 & 7 & positive regulation of lymphocyte differentiation \\
\hline
\end{tabular}}
\end{table}
|
PMC3053315_table_7
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Variables} & \textbf{ICC} & \textbf{95\%} & \textbf{CI} & \textbf{SEM [°]} & \textbf{P value} \\
\hline
[30]. consid- Plurimeter SS—photo SS & 0.93 & 0.89 & 0.95 & 1.2 & 0.712 \\
\hline
Plurimeter LL—photo LL & 0.97 & 0.93 & 0.98 & 0.9 & 0.425 \\
\hline
Plurimeter TK—photo TK & 0.95 & 0.93 & 0.97 & 1.4 & 0.945 \\
\hline
\end{tabular}}
\end{table}
|
PMC5738151_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Variables} & \textbf{1} & \textbf{2} & \textbf{3} & \textbf{4} & \textbf{5} & \textbf{6} & \textbf{7} & \textbf{8} & \textbf{9} & \textbf{10} & \textbf{11} & \textbf{12} & \textbf{13} & \textbf{14} \\
\hline
Total Score DAS & 0.45*** & 0.22** & 0.73** & 0.57*** & 0.27*** & 0.21** & 0.41* & 0.23*** & 0.55** & 0.34*** & 0.35*** & 0.33*** & 0.53*** & 0.49*** \\
\hline
Stress communication_SP & 0.37*** & 0.35*** & 0.31*** & 0.27*** & 0.24** & 0.20** & 0.06 & 0.29*** & 0.29*** & 0.33*** & 0.39*** & 0.03 & 0.23** & 0.12 \\
\hline
Emotion-focused_SP & 0.42*** & 0.41*** & 0.29*** & 0.58*** & 0.38*** & 0.27*** & 0.31*** & 0.35*** & 0.59*** & 0.46*** & 0.41*** & 0.26** & 0.67*** & 0.54*** \\
\hline
Problem-focused_SP & 0.32*** & 0.27** & 0.51*** & 0.20** & 0.57*** & 0.41*** & 0.39*** & 0.49*** & 0.42*** & 0.24** & 0.30*** & 0.42*** & 0.45*** & 0.28*** \\
\hline
Delegated_SP & 0.23** & 0.11 & 0.33*** & 0.28*** & 0.07 & 0.36*** & 0.24** & 0.34*** & 0.26** & 0.14 & 0.18* & 0.22** & 0.25** & 0.09 \\
\hline
Negative_SP & 0.28** & 0.15* & 0.38*** & 0.09 & 0.04 & 0.61*** & 0.08 & 0.43*** & 0.19* & 0.08 & 0.22** & 0.07 & 0.19* & 0.09 \\
\hline
Stress communication_OP & 0.40*** & 0.30*** & 0.32*** & 0.43*** & 0.32*** & 0.08 & 0.06 & 0.07 & 0.39*** & 0.26** & 0.14 & 0.65*** & 0.25** & 0.168* \\
\hline
Emotion-focused_OP & 0.52*** & 0.46*** & 0.63*** & 0.39*** & 0.21** & 0.29** & 0.34*** & 0.47*** & 0.21** & 0.22** & 0.24** & 0.14 & 0.23** & 0.14 \\
\hline
Problem-focused_OP & 0.33*** & 0.35*** & 0.42*** & 0.33*** & 0.13 & 0.18* & 0.14 & 0.48*** & 0.19* & 0.62*** & 0.54*** & 0.42*** & 0.58*** & 0.53*** \\
\hline
Delegated_OP & 0.29*** & 0.42*** & 0.40*** & 0.28*** & 0.24** & 0.17* & 0.26** & 0.55*** & 0.37*** & 0.22** & 0.55*** & 0.22** & 0.39*** & 0.37*** \\
\hline
Negative_OP & 0.31*** & 0.19* & 0.45*** & 0.18* & 0.16* & 0.73*** & 0.17* & 0.38*** & 0.25** & 0.27*** & 0.33*** & 0.15 & 0.44*** & 0.36*** \\
\hline
Common & 0.68*** & 0.47*** & 0.60*** & 0.39** & 0.24** & 0.26** & 0.36*** & 0.61*** & 0.50*** & 0.40*** & 0.33*** & 0.52*** & 0.22** & 0.24** \\
\hline
Satisfaction & 0.65*** & 0.40*** & 0.54*** & 0.33*** & 0.16* & 0.24** & 0.28*** & 0.60*** & 0.45*** & 0.43*** & 0.33*** & 0.72*** & 0.43*** & 0.66*** \\
\hline
Efficacy & 0.55*** & 0.32*** & 0.47*** & 0.36*** & 0.14 & 0.21** & 0.28*** & 0.58*** & 0.37*** & 0.43*** & 0.28*** & 0.70*** & 0.84*** & 0.28*** \\
\hline
\end{tabular}}
\end{table}
|
PMC6418016_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Medication} & \textbf{Overall Healed} & \textbf{Failed} & \textbf{Heal Rate} & \textbf{Lower CI} & \textbf{Upper CI} & \textbf{Elderly Healed} & \textbf{Failed} & \textbf{Heal Rate} \\
\hline
\\
\hline
No medications at all & 1,765 & 61 & 96.7\% & 95.8\% & 97.5\% & 228 & 11 & 95.4\% \\
\hline
Non-NSAID analgesic & 301 & 19 & 94.1\% & 91.5\% & 96.7\% & 48 & 4 & 92.3\% \\
\hline
Prescription NSAIDs & 159 & 14 & 91.9\% & 87.8\% & 96.0\% & 40 & 4 & 90.9\% \\
\hline
Anticoagulants & 107 & 9 & 92.2\% & 87.4\% & 97.1\% & 54 & 2 & 96.4\% \\
\hline
Non-prescription NSAIDs & 104 & 3 & 97.2\% & 94.1\% & 100.0\% & 31 & 0 & 100.0\% \\
\hline
Steroids & 93 & 8 & 92.1\% & 86.8\% & 97.3\% & 30 & 5 & 85.7\% \\
\hline
Antibiotics & 80 & 4 & 95.2\% & 90.7\% & 99.8\% & 14 & 2 & 87.5\% \\
\hline
Insulin & 75 & 6 & 92.6\% & 86.9\% & 98.3\% & 36 & 2 & 94.7\% \\
\hline
Calcium channel blockers & 62 & 6 & 91.2\% & 84.4\% & 97.9\% & 37 & 3 & 92.5\% \\
\hline
\end{tabular}}
\end{table}
|
PMC4357153_table_6
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Isolate reference} & \textbf{∗Matching nucleotides/ identity} & \textbf{∗∗Closest related species} \\
\hline
TOMC MS1 & 855 bp $\mid$ 99\% & Bacillus drentensis $\mid$gi$\mid$828177967$\mid$ KP407110.1 \\
\hline
TOMC MS2 & 694 bp $\mid$ 99\% & Bacillus asahii $\mid$gi$\mid$238800438$\mid$gb$\mid$ FJ973525.1 \\
\hline
TOMC MS3 & 704 bp $\mid$ 100\% & Staphylococcus epidermis $\mid$gi$\mid$955475110$\mid$ KT633374.1 \\
\hline
TOMC MS4 & 624 bp $\mid$ 100\% & Bacillus flexus $\mid$gi$\mid$954050805$\mid$ KT720056.1 \\
\hline
TOMC MS5 & 709 bp $\mid$ 99\% & Bacillus selenatarsenatis $\mid$gi$\mid$309253939$\mid$ HQ202857.1 \\
\hline
TOMC MS6 & 794 bp $\mid$ 97\% & Bacillus alcalophilus $\mid$gi$\mid$343965881$\mid$ JN540804.1 \\
\hline
TOMC MS7 & 948 bp $\mid$ 100\% & Enterococcus faecium $\mid$gi$\mid$946576338$\mid$ KR909902.1 \\
\hline
TOMC MS8 & 934 bp $\mid$ 99\% & Bacillus alkalisediminis $\mid$gi$\mid$194239250$\mid$ AM051268.2 \\
\hline
\end{tabular}}
\end{table}
|
PMC4987347_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{PON1 Q192R Premenopausal Controls, n (\%) Cases by stage Local, n (\%) OR (95\% CI)a Advanced, n (\%) OR (95\% CI)a Postmenopausal Controls, n (\%) Cases by stage Local, n (\%) OR (95\% CI)a Advanced, n (\%) OR (95\% CI)a} & \textbf{QQ 144 (62.6) 70 (63.6) 1.0 65 (84.4) 1.0 196 (62.4) 221 (96.9) 1.0 128 (96.9) 1.0} & \textbf{QR 64 (27.8) 30 (27.3) 0.96 (0.55–1.60) 11 (14.3) 0.42 (0.23–0.86) 88 (28.0) 6 (2.6) 0.06 (0.01–0.12) 3 (2.3) 0.04 (0.01–0.16)} & \textbf{RR 22 (9.6) 10 (9.1) 0.94 (0.32–2.17)b 1 (1.3) 0.23 (0.06–0.85)c 30 (9.6) 1 (0.50) 0.04 (0.00–0.23)d 1 (0.8) 0.02 (0.00–0.25)e} & \textbf{QR and RR 86 (37.4) 40 (36.4) 0.95 (0.60–1.62) 12 (15.6) 0.33 (0.14–0.60) 118 (37.6) 7 (3.1) 0.05 (0.00–0.10) 4 (3.1) 0.05 (0.01–0.11)} \\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
PON1 L55M & LL & LM & MM & LM and MM \\
\hline
\multicolumn{5}{|l|}{Premenopausal} \\
\hline
Controls, n (\%) & 78 (33.9) & 70 (30.4) & 82 (35.7) & 152 (66.1) \\
\hline
\multicolumn{5}{|l|}{Cases by stage} \\
\hline
Local, n (\%) & 16 (14.6) & 25 (22.7) & 69 (62.7) & 94 (85.4) \\
\hline
OR (95\% CI)a & 1.0 & 1.71 (0.78–2.99) & 4.12 (2.13–7.98)f & 3.05 (1.63–5.78) \\
\hline
Advanced, n (\%) & 14 (18.2) & 8 (10.4) & 55 (71.4) & 63 (81.8) \\
\hline
OR (95\% CI)a & 1.0 & 0.62 (0.22–1.70) & 3.71 (1.80–7.53)g & 2.28 (1.12–4.49) \\
\hline
\multicolumn{5}{|l|}{Postmenopausal} \\
\hline
Controls, n (\%) & 110 (35.0) & 55 (17.5) & 149 (47.5) & 204 (65.0) \\
\hline
\multicolumn{5}{|l|}{Cases by stage} \\
\hline
Local, n (\%) & 49 (21.5) & 52 (22.8) & 127 (55.7) & 179 (78.5) \\
\hline
OR (95\% CI)a & 1.0 & 2.15 (1.28–3.75) & 1.94 (1.26–2.98)h & 1.88 (1.20–2.59) \\
\hline
Advanced, n (\%) & 28 (21.2) & 30 (22.7) & 74 (56.1) & 104 (78.8) \\
\hline
OR (95\% CI)a & 1.0 & 2.16 (1.15–4.22) & 1.98 (1.19–3.36)i & 2.00 (1.18–3.29) \\
\hline
\end{tabular}}
\end{table}
|
PMC2680904_table_6
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Sample ID} & \textbf{Replication} & \textbf{Total clean reads} & \textbf{Total mapped reads} & \textbf{Perfect match} & \textbf{$<$ =2 bp Mismatch} & \textbf{Unique match} & \textbf{Multi-position match} & \textbf{Total unmapped reads} \\
\hline
S1-ER & 1 & 11,449,209 & 7,690,109 & 5,586,546 & 2,103,563 & 6,965,933 & 724,176 & 3,759,100 \\
\hline
& 2 & 12,335,056 & 8,503,080 & 6,180,851 & 2,322,229 & 7,754,062 & 749,018 & 3,831,976 \\
\hline
S1-BR & 1 & 12,023,993 & 7,810,160 & 5,641,877 & 2,168,283 & 7,025,399 & 784,761 & 4,213,833 \\
\hline
& 2 & 12,257,878 & 8,266,679 & 6,035,647 & 2,231,032 & 7,515,875 & 750,804 & 3,991,199 \\
\hline
S2-ER & 1 & 11,446,627 & 7,898,285 & 5,754,463 & 2,143,822 & 7,206,860 & 691,425 & 3,548,342 \\
\hline
& 2 & 12,233,415 & 8,595,851 & 6,260,690 & 2,335,161 & 7,834,426 & 761,425 & 3,637,564 \\
\hline
S2-BR & 1 & 11,613,232 & 7,691,237 & 5,608,986 & 2,082,251 & 7,015,241 & 675,996 & 3,921,995 \\
\hline
& 2 & 11,917,155 & 8,085,290 & 5,876,588 & 2,208,702 & 7,289,596 & 795,694 & 3,831,865 \\
\hline
S3-ER & 1 & 11,802,971 & 8,121,699 & 5,958,191 & 2,163,508 & 7,391,705 & 729,994 & 3,681,272 \\
\hline
& 2 & 12,408,764 & 8,537,515 & 6,189,025 & 2,348,490 & 7,784,021 & 753,494 & 3,871,249 \\
\hline
S3-BR & 1 & 11,421,119 & 7,177,782 & 5,221,853 & 1,955,929 & 6,549,727 & 628,055 & 4,243,337 \\
\hline
& 2 & 11,762,649 & 7,523,532 & 5,479,311 & 2,044,221 & 6,784,105 & 739,427 & 4,239,117 \\
\hline
\end{tabular}}
\end{table}
|
PMC4982202_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Risk Factor, Exposure Metric, Data Sourcea} & \textbf{Optimal} & \textbf{Guidelines/National Goals} \\
\hline
\multicolumn{3}{|l|}{High blood glucose} \\
\hline
Fasting plasma glucose (mmol/l) & 4.9 (0.3) & 5.6 (0.3) [66] \\
\hline
\multicolumn{3}{|l|}{High LDL cholesterol} \\
\hline
LDL cholesterol (mmol/l) & 2.0 (0.4) & 3.1 (0.7) [54] \\
\hline
\multicolumn{3}{|l|}{High blood pressure} \\
\hline
Systolic blood pressure (mm Hg) & 115 (6) & 130 (7) [53] \\
\hline
\multicolumn{3}{|l|}{Overweight/obesity} \\
\hline
Body mass index (kg/m2) & 21 (1) & 22 (1) [67] \\
\hline
\multicolumn{3}{|l|}{Alcohol use} \\
\hline
Current alcohol consumption volumes and patterns & No alcohol useb \\
\hline
Alcohol-related road traffic accidents, national road accident data, 2004 [40] & No alcohol use \\
\hline
\multicolumn{3}{|l|}{Tobacco smoking} \\
\hline
Smoking impact ratio, vital statistics 2007 data [23–25], pooled cohort studies [15,35,36] & No smoking \\
\hline
\multicolumn{3}{|l|}{Physical inactivity} \\
\hline
Intensity of physical activity & Highly active \\
\hline
\multicolumn{3}{|l|}{High dietary trans fatty acids} \\
\hline
Percent of total calories from dietary trans fatty acids & 0.5 (0.05) \\
\hline
\multicolumn{3}{|l|}{Low dietary polyunsaturated fatty acids} \\
\hline
Percent of total calories from dietary polyunsaturated fatty acids & 10 (1) \\
\hline
\multicolumn{3}{|l|}{High dietary salt} \\
\hline
Dietary sodium adjusted for total calories (g/d) & 0.5 (0.05) & 10 (1) [7] \\
\hline
\multicolumn{3}{|l|}{Low intake of fruit and vegetables} \\
\hline
Dietary fruit and vegetable intake adjusted for total calories (g/d) & 600 (50) & 350 (29) [7] \\
\hline
\multicolumn{3}{|l|}{Hepatitis B virus} \\
\hline
Seropositivity for hepatitis B surface antigen, blood donors’ cohort, 1991–1993 [37] & No infection \\
\hline
\multicolumn{3}{|l|}{Hepatitis C virus} \\
\hline
Seropositivity for antibody to hepatitis C, blood donors’ cohort, 1991–1993 [37] & No infection \\
\hline
\multicolumn{3}{|l|}{H. pylori} \\
\hline
Seropositivity for anti–H. pylori immunoglobulin G, multi-center study, late 1990s [38] & No infection \\
\hline
\end{tabular}}
\end{table}
|
PMC3265534_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{men} & \multicolumn{2}{|l|}{\textbf{women}} \\
\hline
& & \textbf{non-pregnant} & \textbf{pregnant} & \textbf{p-value} \\
\hline
n & 10 & 10 & 10 \\
\hline
age (year) & 26 ($\pm$10) & 27 ($\pm$6) & 27 ($\pm$3) & 0.899 \\
\hline
aortic root at baseline (mm) & 40.8 ($\pm$3.52) & 36.9 ($\pm$2.97) & 35 ($\pm$3.40) & 0.002a \\
\hline
Z-scores at baseline & 2.67 ($\pm$1.23) & 2.87 ($\pm$1.24) & 1.76 ($\pm$1.40) & 0.142 \\
\hline
aortic root at follow-up (mm) & 42.5 ($\pm$2.80) & 37.9 ($\pm$3.10) & 38.7 ($\pm$3.52) & 0.007b \\
\hline
follow-up time (year) & 5.00 ($\pm$2.75) & 5.09 ($\pm$2.66) & 6.63 ($\pm$3.74) & 0.341 \\
\hline
aortic root growth rate (mm/year) & 0.36 ($\pm$0.35) & 0,.2 ($\pm$0.39) & 0.64 ($\pm$0.42) & 0.022c \\
\hline
\end{tabular}}
\end{table}
|
PMC5951569_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{IMD quintile} & \textbf{Female ($\pounds$)} & \textbf{Male ($\pounds$)} & \textbf{Total ($\pounds$)} \\
\hline
Q1 (most deprived) & 1 127 006 663 & 1 065 236 932 & 2 192 243 595 \\
\hline
Q2 & 706 629 004 & 671 287 893 & 1 377 916 897 \\
\hline
Q3 & 410 841 645 & 405 654 922 & 816 496 567 \\
\hline
Q4 & 198 794 943 & 19 012 169 9 & 388 916 642 \\
\hline
Q5 (most affluent)* & − & − & − \\
\hline
Overall & 2 443 272 255 & 2 332 301 446 & 4 775 573 701 \\
\hline
\end{tabular}}
\end{table}
|
PMC5036206_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Treatment} & \textbf{Stage} & \multicolumn{4}{|l|}{\textbf{Response}} \\
\hline
& & \textbf{CR No. (\%)} & \textbf{PR No. (\%)} & \textbf{SD/PD No. (\%)} & \textbf{Total No. (\%)} \\
\hline
\\
\hline
RT & I & 176 (98) & 2 (1) & 1 (1) & 179 (100) \\
\hline
& II & 31 (94) & 2 (6) & 0 & 33 (100) \\
\hline
CT & I & 7 (59) & 4 (33) & 1 (8) & 12 (100) \\
\hline
& II & 33 (66) & 9 (18) & 8 (16) & 50 (100) \\
\hline
CRT & I & 24 (96) & 0 & 1 (4) & 25 (100) \\
\hline
& II & 28 (72) & 7 (18) & 4 (10) & 39 (100) \\
\hline
\end{tabular}}
\end{table}
|
PMC4492987_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{ID\#} & \textbf{ALT pre/ post-partum, Antiviral Therapy} & \textbf{P Neutral} & \textbf{P Positive} & \textbf{P Purifying} & \textbf{Selectiond} \\
\hline
128 & 15 / 17, No & 0.246 & 1.000 & 0.126 & Neutral \\
\hline
133 & 10 / 24, No & 0.075 & 0.037 & 1.000 & Positive \\
\hline
139 & 23 / 19, No & 0.591 & 0.296 & 1.000 & Neutral \\
\hline
150 & 47 / 23, Yes & 0.094 & 0.049 & 1.000 & Positive \\
\hline
160; 160–2a & 32 / 64, No & 0.297; 0.927 & 0.150; 0.464 & 1.000; 1.000 & Neutral; Neutral \\
\hline
161 & 26 / 47, No & 0.249 & 0.119 & 1.000 & Neutral \\
\hline
172b & 16 / 64, No & 0.140 & 1.000 & 0.067 & Neutral \\
\hline
176–2; 176–3a,b,c & Unknown/18 /7, No & 0.946; 0.508 & 1.000; 0.254 & 0.473; 1.000 & Neutral; Neutral \\
\hline
188 & 34/16, No & 0.204 & 0.105 & 1.000 & Neutral \\
\hline
196; 196–2a,b & 12 / 29, No & 0.806; 0.022 & 1.000; 0.011 & 0.403; 1.000 & Neutral; Positive \\
\hline
205 & 27 / 25, No & 0.305 & 0.154 & 1.000 & Neutral \\
\hline
215 & 43 / 41, No & 0.367 & 0.183 & 1.000 & Neutral \\
\hline
217 & 29 / 19, No & 0.521 & 0.267 & 1.000 & Neutral \\
\hline
223; 223–2 a & 20 / 56, Yes & 1.000 & 1.000 & 1.000 & Neutral \\
\hline
226; 226–2a & 29 / 32, No & 0.931; 0.900 & 1.000; 1.000 & 0.466; 0.450 & Neutral; Neutral \\
\hline
231 & 32 / 13, No & 0.374 & 0.188 & 1.000 & Neutral \\
\hline
233; 233–2a,b & 19 / 33, Yes & 0.703; 0.643 & 0.350; 1.000 & 1.000; 0.322 & Neutral; Neutral \\
\hline
239 & 6 / 26, Yes & 0.031 & 0.014 & 1.000 & Positive \\
\hline
243 & 15 / 16, Yes & 0.223 & 1.000 & 0.104 & Neutral \\
\hline
260 & 11/ 7, /No & 0.292 & 1.000 & 0.143 & Neutral \\
\hline
\end{tabular}}
\end{table}
|
PMC4608582_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& & \multicolumn{2}{|l|}{\textbf{Tromsø 4 (1994–1995)}} & \multicolumn{2}{|l|}{\textbf{Tromsø 6 (2007–2008)}} & \multicolumn{2}{|l|}{\textbf{Changes between Tromsø 4 and Tromsø 6}} \\
\hline
\textbf{Age in 1994 (birth year)} & \textbf{n} & \textbf{Mean (SD)b} & \textbf{\% obese} & \textbf{Mean (SD)} & \textbf{\% obese} & \textbf{Mean (95 \% CI)c} & \textbf{Absolute change in \% obese (relative to 1994, \%)} \\
\hline
\multicolumn{8}{|l|}{Men} \\
\hline
25–34 (1960–69) & 62 & 88.4 (7.8) & 4.8 & 98.2 (10.0) & 30.7 & 9.8 (7.9, 11.6) & 25.8 (+538 \%) \\
\hline
35–44 (1950–59) & 89 & 90.9 (7.4) & 7.9 & 98.2 (9.1) & 33.7 & 7.3 (5.8, 8.8) & 25.8 (+327 \%) \\
\hline
45–54 (1940–49) & 326 & 96.1 (8.5) & 21.8 & 102.3 (10.5) & 46.6 & 6.2 (5.5, 7.0) & 24.8 (+114 \%) \\
\hline
55–64 (1930–39) & 850 & 94.8 (8.2) & 18.0 & 100.6 (10.2) & 40.4 & 5.8 (5.3, 6.3) & 22.4 (+124 \%) \\
\hline
65–69 (1925–29) & 182 & 95.1 (7.8) & 17.6 & 100.8 (11.0) & 43.4 & 5.7 (4.7, 6.8) & 25.8 (+147 \%) \\
\hline
Total & 1,509 & 94.6 (8.3) & 17.6 & 100.8 (10.4) & 41.3 & 6.1 (5.8, 6.5) & 23.7 (+135 \%) \\
\hline
\multicolumn{8}{|l|}{Women} \\
\hline
25–34 (1960–69) & 76 & 76.9 (9.1) & 10.5 & 86.3 (10.1) & 36.8 & 9.4 (7.4, 11.4) & 26.3 (+250 \%) \\
\hline
35–44 (1950–59) & 134 & 79.2 (9.9) & 14.9 & 91.3 (12.3) & 57.5 & 12.1 (10.6, 13.6) & 42.5 (+285 \%) \\
\hline
45–54 (1940–49) & 158 & 80.7 (8.6) & 17.7 & 90.2 (10.0) & 58.2 & 9.6 (8.3, 10.8) & 40.5 (+229 \%) \\
\hline
55–64 (1930–39) & 973 & 83.8 (9.8) & 26.6 & 91.9 (11.6) & 61.4 & 8.1 (7.5, 8.6) & 34.7 (+130 \%) \\
\hline
65–69 (1925–29) & 294 & 86.5 (9.7) & 42.9 & 93.3 (12.0) & 64.0 & 6.8 (5.8, 7.8) & 21.1 (+49 \%) \\
\hline
Total & 1,635 & 83.3 (9.9) & 27.0 & 91.7 (11.6) & 60.1 & 8.4 (8.0, 8.8) & 33.1 (+123 \%) \\
\hline
\end{tabular}}
\end{table}
|
PMC5031316_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Year} & \textbf{Estimated population\#} & \textbf{Birth cohort} & \textbf{Vaccination coverage*} & \textbf{Vaccine efficacy**} & \textbf{Children susceptible} & \textbf{Cumulated susceptible population} \\
\hline
1988 & 2,076,264 & 44,432 & 103.19\% & 85\% & 5,459 & 5,459 \\
\hline
1989 & 2,091,648 & 46,853 & 105.50\% & 85\% & 4,837 & 10,296 \\
\hline
1990 & 2,107,146 & 44,461 & 101.67\% & 85\% & 6,038 & 16,334 \\
\hline
1991 & 2,122,759 & 44,153 & 100.65\% & 85\% & 6,378 & 22,712 \\
\hline
1992 & 2,138,488 & 44,267 & 104.57\% & 85\% & 4,921 & 27,633 \\
\hline
1993 & 2,154,333 & 42,009 & 102.70\% & 85\% & 5,337 & 32,970 \\
\hline
1994 & 2,170,295 & 41,670 & 102.51\% & 85\% & 5,362 & 38,332 \\
\hline
1995 & 2,186,376 & 44,383 & 104.92\% & 85\% & 4,803 & 43,135 \\
\hline
1996 & 2,202,576 & 42,289 & 101.57\% & 85\% & 5,779 & 48,913 \\
\hline
1997 & 2,218,896 & 42,603 & 100.74\% & 85\% & 6,124 & 55,037 \\
\hline
1998 & 2,235,337 & 42,918 & 99.28\% & 85\% & 6,700 & 61,737 \\
\hline
1999 & 2,251,900 & 43,462 & 101.25\% & 85\% & 6,058 & 67,795 \\
\hline
2000 & 2,268,586 & 43,784 & 101.13\% & 85\% & 6,148 & 73,944 \\
\hline
2001 & 2,285,395 & 44,108 & 105.18\% & 85\% & 4,674 & 78,617 \\
\hline
2002 & 2,302,329 & 44,435 & 102.56\% & 85\% & 5,697 & 84,314 \\
\hline
2003 & 2,319,388 & 44,764 & 101.46\% & 85\% & 6,159 & 90,473 \\
\hline
2004 & 2,336,574 & 45,096 & 99.57\% & 85\% & 6,928 & 97,401 \\
\hline
\end{tabular}}
\end{table}
|
PMC1586205_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Sample used in biopanning experimentsa} & \textbf{CaSR consensus peptide sequencesb} & \textbf{Amino acid residues of CaSRc} & \textbf{Number of clones with consensus sequence (\%)} \\
\hline
APS1-2 & AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 26–71 & 9/20 (45) \\
\hline
& TVSKALAEATLSFVAQNKIDSLNLDEFCNCSE & 103–133 & 3/20 (15) \\
\hline
APS1-3 & HFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 41–71 & 8/16 (50) \\
\hline
& KALAEATLSFVAQNKIDSLNLDEFCN & 106–130 & 2/16 (13) \\
\hline
APS1-4 & HFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 41-71 & 5/20 (25) \\
\hline
& FVAQNKIDSLNLD & 114–126 & 3/20 (15) \\
\hline
APS1-5 & LGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFR & 34–69 & 3/20 (15) \\
\hline
APS1-6 & AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 26-71 & 9/20 (45) \\
\hline
& SRLLSNKNQFKSFLRTIPNDEHQAT & 171–195 & 2/20 (10) \\
\hline
APS1-7 & GDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFR & 30–69 & 8/20 (40) \\
\hline
& TVSKALAEATLSFVAQNKIDSLNLDEFCNCSE & 103–133 & 3/20 (15) \\
\hline
APS1-8 & No consensus peptide sequence defined & — & — \\
\hline
APS1-9 & QKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 27–71 & 2/20 (10) \\
\hline
APS1-10 & AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 26–71 & 10/20 (50) \\
\hline
& SRLLSNKNQFKSFLRTIPNDEHQAT & 171–195 & 3/20 (15) \\
\hline
APS1-11 & QKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 27–71 & 2/20 (10) \\
\hline
APS1-12 & No consensus peptide sequence defined & — & — \\
\hline
APS1-13 & HFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 41–71 & 10/20 (50) \\
\hline
& SRLLSNKNQFKSFLRTIPNDEHQAT & 171–195 & 3/20 (15) \\
\hline
APS1-14 & HFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 41–71 & 8/20 (40) \\
\hline
& SRLLSNKNQFKSFLRTIPNDEHQAT & 171–195 & 2/20 (10) \\
\hline
APS1-15 & QKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 27–71 & 3/20 (15) \\
\hline
& TVSKALAEATLSFVAQNKIDSLNLDEFCNCSE & 103–133 & 3/20 (15) \\
\hline
AHH & HFGVAAKDQDLKSRPESVECIRYNFRGFRWL & 41–71 & 9/20 (45) \\
\hline
Anti-CaSR Abd & YGPDQRAQ & 20–27 & 10/20 (50) \\
\hline
Anti-CaSR mAbe & ADDDYGRPGIEKFREEAEERDICI & 214–237 & 10/20 (50) \\
\hline
\end{tabular}}
\end{table}
|
PMC3153323_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \textbf{Liver R2(s-1)} & \textbf{Bone Marrow R2(s-1)} & \textbf{Spleen R2(s-1)} & \textbf{Kidney R2(s-1)} & \textbf{Heart R2*(s-1)} \\
\hline
Control & 33.7 $\pm$ 7.6 & 21.8 $\pm$ 4.9 & 19.6 $\pm$ 2.8 & 17.1 $\pm$ 2.9 \\
\hline
& (21–45) & (14.5–34.4) & (14.2–23.5) & (12.2–22) \\
\hline
SCD & 123.7 $\pm$ 108.1 & 43.2 $\pm$ 21.1 & 67.2 $\pm$ 31.5 & 27.1 $\pm$ 8.7 & 31.6 $\pm$ 6.3 \\
\hline
& (26.7–366) & (18.3–105.7) & (23.9–149) & (12.6–54.4) & (22–46.2) \\
\hline
PNH & 144.3 $\pm$ 79.8 & 36.1 $\pm$ 19.2 & 52.3 $\pm$ 31.8 & 18.1 $\pm$ 3.5 & 33.2 $\pm$ 10.6 \\
\hline
& (48.8–354.9) & (17.8–90.6) & (20.5–130.9) & (14.6–21.5) & (18–59.8) \\
\hline
NTDT & 94.7 $\pm$ 36.3 & 32.6 $\pm$ 7.0 & 26.4 $\pm$ 8.2 & 16.1 $\pm$ 2.6 & 26.6 $\pm$ 5.2 \\
\hline
& (52.5–163.0) & (23.3–45.1) & (11.0–36.3) & (12.6–20.3) & (22.0–33.4) \\
\hline
\end{tabular}}
\end{table}
|
PMC4583270_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Verb generation fMRI task} & \textbf{BADA stimuli} \\
\hline
Bicchiere (glass) & Versare (to pour) \\
\hline
Chitarra (guitar) & Suonare (to sing) \\
\hline
Fucile (rifle) & Sparare (to shoot) \\
\hline
Fiasco (flask) & Versare (to pour) rep \\
\hline
Violino (violin) & Suonare (to sing) rep \\
\hline
Telefono (telephon) & Telefonare (to call) \\
\hline
Fisarmonica (accordion) & Suonare (to sing) rep \\
\hline
Forbici (scissors) & Tagliare (to cut) \\
\hline
Gelato (ice cream) & Leccare (to lick) \\
\hline
Martello (hammer) & Scolpire (to sculpt) \\
\hline
Pala (shovel) & Scavare (to dig) \\
\hline
Sega (saw) & Segare (to saw) \\
\hline
Automobile (car) & Fischiare (to whistle) \\
\hline
Annaffiatoio (watering can) & Annegare (to drown) \\
\hline
Scala (stairway) & Bussare (to knock) \\
\hline
Chiave (key) & Correre (to run) \\
\hline
Ago (needle) & Accendere (to light) \\
\hline
Pattini (skate) & Scavalcare (to climb over) \\
\hline
Penna (pen) & Cancellare (to delete) \\
\hline
Pettine (comb) & Baciare (to kiss) \\
\hline
Righello (ruler) & Indicare (to indicate) \\
\hline
Scopa (broom) & Giurare (to take an oath) \\
\hline
Corda ( rope) & Seminare (to sow) \\
\hline
Bicicletta (bicycle) & Stirare (to iron) \\
\hline
& Spingere (to push) \\
\hline
& Applaudire (to clap) \\
\hline
& Costruire (to build) \\
\hline
& Dormire (to sleep) \\
\hline
& Azzannare (to snap at) \\
\hline
& Sudare (to sweat) \\
\hline
& Nuotare (to swim) \\
\hline
\end{tabular}}
\end{table}
|
PMC3675382_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Time} & \textbf{Control} & \textbf{Sw} & \textbf{DEP} & \textbf{DEP + Sw} \\
\hline
10° min & 3.5$\pm$ 1.1 & 4.1$\pm$ 0.7 & 4.4$\pm$ 1.4 & 3.7$\pm$ 1.6 \\
\hline
30° min & 5.6$\pm$ 1.4* & 5.9$\pm$ 0.3* & 6.2$\pm$ 1.2* & 5.7$\pm$ 0.8* \\
\hline
\end{tabular}}
\end{table}
|
PMC4557939_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Reasons} & \textbf{N\% out of 36 subjects} & \textbf{N\% out of 216 subjects} \\
\hline
Heavy personal activity load & 10 (27.8) & 10 (4.6) \\
\hline
Poor health & 16 (44.4) & 16 (7.4) \\
\hline
Caregiver for sick husband or wife & 4 (11.1) & 4 (1.9) \\
\hline
Computer stress & 2 (5.6) & 2 (0.9) \\
\hline
Unknown & 4 (11.1) & 4 (1.9) \\
\hline
Total & 36 (100) & 36 (16.7) \\
\hline
\end{tabular}}
\end{table}
|
PMC3607803_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{IL-2} & \textbf{IL-2+ART} & \textbf{Control} & \textbf{Total} \\
\hline
\multicolumn{5}{|l|}{Age (years)} \\
\hline
Median & 35 & 35 & 36 & 36 \\
\hline
Interquartile range & & & & 30–44 \\
\hline
Gender (\% female) & 19.1 & 14.9 & 17.6 & 17.2 \\
\hline
\multicolumn{5}{|l|}{Race (\%)} \\
\hline
Asian & 24.7 & 26.4 & 24.2 & 25.1 \\
\hline
Black & 4.5 & 4.6 & 8.8 & 6.0 \\
\hline
White/other & 70.8 & 69.0 & 67.0 & 68.9 \\
\hline
\multicolumn{5}{|l|}{CD4+ count (cells/mm3)} \\
\hline
Median & 399 & 425 & 432 & 419 \\
\hline
Interquartile range & & & & 359–512 \\
\hline
\multicolumn{5}{|l|}{HIV-RNA (copies)} \\
\hline
Median & 23,508 & 21,881 & 24,328 & 22,384 \\
\hline
Interquartile range & & & & 7,189–61,169 \\
\hline
\multicolumn{5}{|l|}{Medication Use and History} \\
\hline
Antiretroviral (ART) naı¨ve (\%) & 76.4 & 87.4 & 72.5 & 78.7 \\
\hline
Months since last ART use* (median) & 36.9 & 28.9 & 32.0 & 21.3 \\
\hline
Current OI prophylaxis use (\%) & 3.4 & 2.3 & 2.2 & 2.6 \\
\hline
\multicolumn{5}{|l|}{Likely mode of HIV transmission** (\%)} \\
\hline
Person of same sex & 60.7 & 56.3 & 61.5 & 59.6 \\
\hline
Person of opposite sex & 38.2 & 41.4 & 37.4 & 39.0 \\
\hline
Injection drug use & 2.2 & 4.6 & 0.0 & 2.2 \\
\hline
Blood products & 1.1 & 1.1 & 0.0 & 0.7 \\
\hline
Other or unknown & 2.2 & 2.3 & 2.2 & 2.2 \\
\hline
\multicolumn{5}{|l|}{Hepatitis Status (\%)} \\
\hline
Hepatitis B surface antigen positive & 5.6 & 0.0 & 5.6 & 3.8 \\
\hline
Hepatitis C antibody positive & 5.7 & 5.7 & 7.8 & 6.4 \\
\hline
\multicolumn{5}{|l|}{BMI (kg/m2)} \\
\hline
Median & 23.5 & 23.2 & 23.6 & 23.4 \\
\hline
Interquartile range & & & & 21.2–26.2 \\
\hline
\multicolumn{5}{|l|}{Total cholesterol (mg/dl)} \\
\hline
Median & 166 & 170 & 170 & 170 \\
\hline
Interquartile range & & & & 147–196 \\
\hline
\end{tabular}}
\end{table}
|
PMC2826395_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\multicolumn{2}{|l|}{were P. falciparum} \\
\hline
18S rRNA & Pf_18S rRNA‑F: AATAACAATGCAAGGCCAATTT \\
\hline
P. & Pf_18S rRNA‑R: CTGCAACAATTTTAATATACGC \\
\hline
LDH & Pf_LDH‑F: AAACCCAGTAGATGTTATGGTAC \\
\hline
the & Pf_LDH‑R: CATTTTATTTCCATGAGCACCTAC \\
\hline
CytB & Pf_CytB‑F: ACTTGTTATCCTCTATTCCAGTAGCAGTAA \\
\hline
human & Pf_CytB‑R: AATCGTTTTATTGTAGGATCACTCACA \\
\hline
\multicolumn{2}{|l|}{the P. yoelii} \\
\hline
yoelii 18S rRNA & Py_18S rRNA‑F: GCAACTCACTTGGCTAGATTCTT \\
\hline
from & Py_18S rRNA‑R: CGGCTTTAACTGTTTGCTTTG \\
\hline
LDH & Py_LDH‑F: GCTCGACTTTATTAGAAGGCCAAT \\
\hline
sam- & Py_LDH‑R: TCGATTACTTGTTCTACACCATTACCA \\
\hline
for P. CytB & Py_CytB‑F: TTTACATTTACATGGTAGCACTAATCCTTT \\
\hline
imme- & Py_CytB‑R: CCTTTTACATCAAGACTTAATAGATTTGGA \\
\hline
\multicolumn{2}{|l|}{FTA P. berghei} \\
\hline
18S rRNA & Pb_18S rRNA‑F: AAGCATTAAATAAAGCGAATACATCCTTAC \\
\hline
for P. & Pb_18S rRNA‑R: GGAGATTGGTTTTGACGTTTATGTG \\
\hline
fal- LDH [15] & Pb_LDH‑F: GGAAGGAGGTTCACAAGCAGGT \\
\hline
& Pb_LDH‑R: TATGCTCTCAGCCAAGTCTGCC \\
\hline
CytB [14] & Pb_CytB‑F: TGGGGACAAATGAGTTACTGG \\
\hline
& Pb_CytB‑R: CAGTGTATCCTCCACATAACCAA \\
\hline
\end{tabular}}
\end{table}
|
PMC4784371_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{C∗} & \textbf{C1 and (C10 + C∗)} & \textbf{(C1 + C∗) and C10} \\
\hline
C3 & 0.841 & 0.968 \\
\hline
C2 & 0.880 & 0.810 \\
\hline
\end{tabular}}
\end{table}
|
PMC4866020_table_5
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
Mn, Atom & Site & Present work & Dominko et al.1) & Arroyo-de Dompablo et al.2) \\
\hline
Li & 4b & 1.02 (6) & 1.0 (1) & 0.9 \\
\hline
Poly- Mn & 2a & 1.89 (5) & 2.1 (1) & 1.77 \\
\hline
Si & 2a & 3.89 (7) & 3.6 (2) & 3.65 \\
\hline
O1 & 2a & 2.02 (9) & 1.9 (3) & 1.75 \\
\hline
O2 & 4b & 1.97 (7) & 1.9 (2) & 1.86 \\
\hline
O3 & 2a & 1.87 (7) & 2.0 (2) & 1.90 \\
\hline
\end{tabular}}
\end{table}
|
PMC3435565_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Sample} & \textbf{Identified proteins} & \textbf{Accession number} & \textbf{Seq. Cov. [\%]} & \textbf{Matching Peptides} & \textbf{Unique Peptides*} & \textbf{Position} & \textbf{Score} & \textbf{Species} \\
\hline
Stick 1 (from M17) & myosin-7 & gi$\mid$41386711 & 19 & 38 & – & – & – & – \\
\hline
& Predicted: myosin-6 & gi$\mid$297479068 & 13 & 26 & – & – & – & – \\
\hline
& myosin light chain 3 & gi$\mid$270483786 & 36 & 6 & AAAAPAPAPAPPPAPEPSK & 19–37 & 49 & Bos taurus, Bison bison bison, Bubalus bubalis \\
\hline
& alpha-actinin-2 & gi$\mid$77736221 & 34 & 28 & – & – & – & – \\
\hline
& Predicted: Low Quality Protein: titin & gi$\mid$297465038 & 1 & 43 & – & – & – & – \\
\hline
& desmin & gi$\mid$2959452 & 37 & 16 & – & – & – & – \\
\hline
& myosin-binding protein C, cardiac-type & gi$\mid$115495853 & 15 & 19 & SIFTVEGAER & 728–737 & 45 & Bos taurus, Bison bison bison, Bos mutus \\
\hline
& & & & & AHNLAGAGPPVTTK & 941–954 & 89 & Bos taurus, Bos mutus \\
\hline
& Serum albumin & gi$\mid$1351907 & 33 & 21 & LVNELTEFAK & 66–75 & 74 & Bos taurus, Bison bison bison, Bubalus bubalis, Bos mutus \\
\hline
& & & & & TCVADESHAGCEK & 76–88 & 74 & Bos taurus, Bison bison bison, Bos mutus \\
\hline
& & & & & DAFLGSFLYEYSR & 347–359 & 42 & Bos indicus, Bos taurus, Bison bison bison, Bubalus bubalis, Bos mutus \\
\hline
& & & & & RPCFSALTPDETYVPK & 508–523 & 51 & Bos indicus, Bos taurus, Bison bison bison, Bubalus bubalis, Bos mutus \\
\hline
& myoglobin & gi$\mid$27806939 & 50 & 6 & HPSDFGADAQAAMSK & 120–134 & 47 & Bos taurus, Bubalus bubalis \\
\hline
& hemoglobin alpha chain & gi$\mid$6006425 & 30 & 4 & VGGHAAEYGAEALER & 18–32 & 82 & Bos taurus, Bison bison bison, Bubalus bubalis, Bos mutus, Bison bonasus, Bos grunniens \\
\hline
& collagen alpha-1(VI) chain precursor & gi$\mid$219804724 & 9 & 10 & AAEYDVVFGER & 990–1000 & 39 & Bos taurus, Bison bison bison, Bubalus bubalis, Bos mutus \\
\hline
& Predicted: collagen alpha-3(VI) chain isoform 4 & gi$\mid$297473452 & 9 & 24 & – & – & – & – \\
\hline
Stick 2 (from M22) & myosin-7 & gi$\mid$41386711 & 15 & 35 & – & – & – & – \\
\hline
& tropomyosin alpha-1 chain & gi$\mid$61888866 & 11 & 4 & – & – & – & – \\
\hline
& tropomyosin 4-like & gi$\mid$296486595 & 15 & 4 & IQLVEEELNRAQER & 56–69 & 39 & Bos taurus, Bison bison bison, Bubalus bubalis, Bos mutus \\
\hline
& Predicted: Low Quality Protein: titin & gi$\mid$297465038 & $<$ 1 & 31 & NGVVLESSDK & 2730–2739 & 19 & Bos taurus \\
\hline
& desmin & gi$\mid$2959452 & 11 & 5 & – & – & – & – \\
\hline
& myosin-binding protein C, cardiac-type & gi$\mid$115495853 & 4 & 5 & – & – & – & – \\
\hline
& Serum albumin & gi$\mid$1351907 & 31 & 21 & YICDNQDTISSK & 286–297 & 25 & Bos indicus, Bos taurus, Bison bison bison, Bubalus bubalis, Bos mutus \\
\hline
& & & & & DAIPENLPPLTADFAEDK & 319–336 & 64 & Bos indicus, Bos taurus \\
\hline
& Hemoglobin subunit alpha-2 & gi$\mid$122286 & 40 & 5 & VGGHAAEYGAEALER & 17–31 & 61 & Bos taurus, Bos grunniens, Bison bison bison, Bos mutus, Bison bonasus \\
\hline
& collagen, type VI, alpha 3-like isoform 3 & gi$\mid$296488813 & $<$ 1 & 8 & – & – & – & – \\
\hline
\end{tabular}}
\end{table}
|
PMC4730899_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{SCN5A positive (n = 40)} & \textbf{SCN5A negative (n = 98)} & \textbf{Volunteers (n = 18)} & \textbf{P value* SCN5A positive vs. SCN5A negative} \\
\hline
Age, years & 45.1614.3 & 43.9612.5 & 42.068.7 & 0.77 \\
\hline
Sex, man/woman (n) & 22/18 & 49/49 & 8/10 & 0.46 \\
\hline
Type of SCN5A mutation, missense/truncation (n) & 33/7 \\
\hline
\multicolumn{5}{|l|}{ECG parameters} \\
\hline
Heart rate, beats per min & 64.7610.1 & 68.8611.0 & & 0.049 \\
\hline
PR, ms & 192.2630.5 & 162.3623.4 & & ,0.001 \\
\hline
QRS, ms & 110.7615.2 & 100.7611.7 & & ,0.001 \\
\hline
QT, ms & 383.9626.5 & 365.3630.7 & & 0.001 \\
\hline
QTc, ms & 396.3628.3 & 387.9624.2 & & 0.09 \\
\hline
S duration in II, ms & 41.2627.2 & 35.2619.8 & & 0.16 \\
\hline
S amplitude in II, mV & 0.2360.23 & 0.1960.15 & & 0.23 \\
\hline
S duration in III, ms & 33.5632.0 & 34.3626.0 & & 0.88 \\
\hline
S amplitude in III, mV & 0.1860.24 & 0.2160.26 & & 0.46 \\
\hline
\end{tabular}}
\end{table}
|
PMC3410911_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Case type} & \textbf{Broad diagnosis} & \textbf{Main reason for admission} & \textbf{Challenging behaviour} & \textbf{Resident carer} & \textbf{\% Appropriateness score} \\
\hline
1 & Depression/anxiety & Risk of deliberate self-harm & Low & Yes & 73.8 \\
\hline
2 & Depression/anxiety & Risk of deliberate self-harm & Low & No & 95.4 \\
\hline
3 & Depression/anxiety & Risk of deliberate self-harm & Medium & Yes & 56.0 \\
\hline
4 & Depression/anxiety & Risk of deliberate self-harm & Medium & No & 78.9 \\
\hline
6 & Depression/anxiety & Other risks & Medium & Yes & 26.2 \\
\hline
7 & Depression/anxiety & Other risks & Medium & No & 54.4 \\
\hline
9 & Depression/anxiety & Behaviour management related & Medium & Yes & 48.0 \\
\hline
10 & Depression/anxiety & Behaviour management related & Medium & No & 28.3 \\
\hline
16 & Depression/anxiety & Assessment/treatment/check medication & Medium & No & 33.3 \\
\hline
21 & Organic & Other risks & Medium & Yes & 35.7 \\
\hline
22 & Organic & Other risks & Medium & No & 41.3 \\
\hline
26 & Organic & Behaviour management related & Medium & Yes & 23.8 \\
\hline
28aa & Organic & Behaviour management related & High & Yes & 28.6 \\
\hline
28ba & Organic & Behaviour management related & High & Yes & 53.8 \\
\hline
29 & Organic & Assessment/treatment/check medication & Medium & Yes & 50.0 \\
\hline
31 & Organic & Assessment/treatment/check medication & High & Yes & 11.8 \\
\hline
40 & Other & Behaviour management related & Medium & Yes & 44.4 \\
\hline
\end{tabular}}
\end{table}
|
PMC4504087_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
& & \multicolumn{4}{|l|}{\textbf{Feeling scale}} & \multicolumn{4}{|l|}{\textbf{Felt arousal scale}} \\
\hline
& & \textbf{Mean} & \textbf{SEM} & \textbf{Median} & \textbf{IQR} & \textbf{Mean} & \textbf{SEM} & \textbf{Median} & \textbf{IQR} \\
\hline
10 Min & Run & 2.7 & 0.3 & 3 & 3 & 1.8 & 0.1 & 2 & 1 \\
\hline
Pre-exercise & Walk & 2.4 & 0.3 & 3 & 3 & 1.8 & 0.2 & 1 & 2 \\
\hline
Min 30 & Run & 3.1 & 0.3 & 3 & 2 & 2.8 & 0.1 & 3 & 1 \\
\hline
& Walk & 2.8 & 0.3 & 3 & 2 & 2.2 & 0.1 & 4 & 1 \\
\hline
Min 60 & Run & 3.3 & 0.3 & 3 & 2 & 3.0 & 0.2 & 3 & 2 \\
\hline
& Walk & 2.7 & 0.3 & 3 & 1 & 2.4 & 0.2 & 2 & 1 \\
\hline
Min 90 & Run & 3.4 & 0.4 & 3 & 2 & 3.3 & 0.2 & 3 & 1 \\
\hline
& Walk & 2.6 & 0.3 & 3 & 1 & 2.5 & 0.2 & 2 & 1 \\
\hline
30 Min & Run & 1.9 & 0.3 & 2 & 2 & 2.3 & 0.2 & 2 & 2 \\
\hline
Post-exercise & Walk & 1.6 & 0.3 & 2 & 3 & 2.0 & 0.2 & 2 & 2 \\
\hline
\end{tabular}}
\end{table}
|
PMC6232759_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Group A (n = 35)} & \textbf{Group G (n = 35)} & \textbf{P-value} \\
\hline
Age (years) & 56 $\pm$ 15 (19–75) & 55 $\pm$ 13 (24–75) & 0.772 \\
\hline
Gender (male/female, n) & 22/13 & 21/14 & 0.811 \\
\hline
Weight (Kg) & 64.6 $\pm$ 12.2 (44–87) & 65.3 $\pm$ 10.8 (46–88) & 0.76 \\
\hline
Height (cm) & 167 $\pm$ 8 (154–180) & 165 $\pm$ 8 (148–180) & 0.483 \\
\hline
Mouth opening (cm) & 4.4 $\pm$ 0.6 (3.5-6) & 4.3 $\pm$ 0.5 (3.5-6) & 0.425 \\
\hline
TMD (cm) & 7.5 $\pm$ 1.1 (5–9.5) & 7.2 $\pm$ 1.0 (5–10) & 0.316 \\
\hline
Mallampati classification (I/II/III/IV, n) & 17/13/5/0 & 18/14/3/0 & 0.307 \\
\hline
A-OJM ($>$30°, n) & 34 & 35 & 0.314 \\
\hline
ULBT (A/B/C, n) & 27/7/1 & 22/13/0 & 0.064 \\
\hline
\end{tabular}}
\end{table}
|
PMC4419514_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
& \textbf{Cont 3 M} & \textbf{Cont 6 M} & \textbf{Cont 11 M} & \textbf{Cont 21 M} & \textbf{Inulin 3 M} & \textbf{Inulin 6 M} & \textbf{Inulin 11 M} & \textbf{Inulin 21 M} & \textbf{inulin} & \textbf{age} & \textbf{interaction} \\
\hline
Plasma Ca, mg/L & 98 $\pm$ 4 & 98 $\pm$ 5 & 95 $\pm$ 6 & 100 $\pm$ 5 & 102 $\pm$ 5 & 99 $\pm$ 4 & 98 $\pm$ 3 & 100 $\pm$ 4 & 0.0601 & 0.0619 & NS \\
\hline
Tibia weight, mg dw & 480 $\pm$ 42 & 630 $\pm$ 80 & 717 $\pm$ 89 & 630 $\pm$ 93 & 489 $\pm$ 66 & 617 $\pm$ 66 & 841 $\pm$ 92 & 648 $\pm$ 47 & 0.042 & $<$0.0001 & 0.023 \\
\hline
Bone Ca, mg/g dw & 207 $\pm$ 21 & 214 $\pm$ 15 & 216 $\pm$ 15 & 215 $\pm$ 21 & 205 $\pm$ 13 & 215 $\pm$ 18 & 202 $\pm$ 14 & 228 $\pm$ 7 & NS & 0.018 & 0.0639 \\
\hline
Plasma Mg, mg/L & 17.9 $\pm$ 1.1 & 17.7 $\pm$ 1.1 & 17.2 $\pm$ 1.0 & 16.9 $\pm$ 1.3 & 17.6 $\pm$ 1.1 & 17.9 $\pm$ 1.3 & 18.2 $\pm$ 1.5 & 18.2 $\pm$ 1.7 & 0.0570 & NS & NS \\
\hline
Erythrocyte Mg, mg/L & 45.4 $\pm$ 3.8 & 44.2 $\pm$ 4.7 & 42.5 $\pm$ 3.4 & 43.4 $\pm$ 3.0 & 44.9 $\pm$ 4.9 & 43.8 $\pm$ 2.5 & 44.3 $\pm$ 3.6 & 43.8 $\pm$ 3.9 & NS & NS & NS \\
\hline
Bone Mg, mg/g dw & 3.92 $\pm$ 0.10 & 3.79 $\pm$ 0.08 & 3.72 $\pm$ 0.08 & 3.76 $\pm$ 0.08 & 3.91 $\pm$ 0.10 & 3.72 $\pm$ 0.07 & 3.73 $\pm$ 0.09 & 3.72 $\pm$ 0.09 & NS & $<$0.0001 & NS \\
\hline
\end{tabular}}
\end{table}
|
PMC1283151_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{U11} & \textbf{U22} & \textbf{U33} & \textbf{U12} & \textbf{U13} & \textbf{U23} \\
\hline
C1 & 0.0323 (12) & 0.0467 (13) & 0.0504 (14) & 0.0078 (10) & 0.0086 (10) & 0.0101 (11) \\
\hline
N1 & 0.0608 (16) & 0.0709 (16) & 0.0496 (14) & 0.0068 (13) & 0.0017 (11) & 0.0094 (11) \\
\hline
O1 & 0.113 (2) & 0.131 (2) & 0.0458 (13) & −0.0138 (16) & 0.0034 (12) & 0.0245 (13) \\
\hline
N2 & 0.0512 (14) & 0.0510 (13) & 0.0797 (17) & 0.0095 (11) & 0.0225 (13) & 0.0255 (12) \\
\hline
C2 & 0.0424 (14) & 0.0518 (15) & 0.0425 (13) & 0.0125 (11) & 0.0041 (10) & 0.0101 (11) \\
\hline
O2 & 0.0575 (13) & 0.1052 (18) & 0.0627 (13) & −0.0106 (12) & −0.0020 (10) & 0.0039 (12) \\
\hline
N3 & 0.0292 (10) & 0.0650 (13) & 0.0446 (11) & 0.0026 (9) & 0.0098 (8) & 0.0172 (9) \\
\hline
C3 & 0.0528 (15) & 0.0544 (15) & 0.0489 (14) & 0.0174 (12) & 0.0161 (12) & 0.0207 (12) \\
\hline
O3 & 0.0941 (18) & 0.1021 (18) & 0.0914 (17) & −0.0079 (14) & 0.0313 (14) & 0.0522 (14) \\
\hline
C4 & 0.0396 (13) & 0.0423 (13) & 0.0586 (15) & 0.0087 (10) & 0.0153 (11) & 0.0176 (11) \\
\hline
O4 & 0.0597 (13) & 0.0651 (13) & 0.0940 (16) & −0.0137 (10) & 0.0088 (12) & 0.0193 (11) \\
\hline
O5 & 0.0287 (9) & 0.0861 (14) & 0.0596 (11) & 0.0045 (8) & 0.0149 (8) & 0.0164 (9) \\
\hline
C5 & 0.0330 (12) & 0.0439 (13) & 0.0489 (13) & 0.0095 (10) & 0.0090 (10) & 0.0098 (11) \\
\hline
C6 & 0.0287 (11) & 0.0446 (13) & 0.0458 (13) & 0.0100 (10) & 0.0090 (9) & 0.0114 (10) \\
\hline
C7 & 0.0270 (12) & 0.0501 (14) & 0.0468 (13) & 0.0074 (10) & 0.0115 (10) & 0.0089 (10) \\
\hline
C8 & 0.0454 (14) & 0.0633 (17) & 0.0415 (14) & 0.0050 (12) & 0.0099 (11) & 0.0125 (12) \\
\hline
C9 & 0.089 (2) & 0.0671 (19) & 0.0588 (18) & 0.0082 (17) & 0.0087 (16) & 0.0185 (15) \\
\hline
\end{tabular}}
\end{table}
|
PMC3099801_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Immunoreactivitya} & \textbf{0\%} & \textbf{$\leq$50\%} & \textbf{$>$50\%} & \textbf{t-test} \\
\hline
p63 in normal ductsb & 0 & 0 & 100\% \\
\hline
p63 in DCIS & 4\% & 52\% & 44\% & p=.01 \\
\hline
CD31 in normal vessels & 0 & 0 & 100\% \\
\hline
CD31 in LVI & 75\% & 20\% & 5\% & p=.01 \\
\hline
D2-40c in normal lymphatics & 0 & 0 & 100\% \\
\hline
D2-40 in LVI & 55\% & 34\% & 11\% & p=.01 \\
\hline
p63 in normal vessels/lymphatics & 100\% & 0\% & 0\% \\
\hline
p63 in LVI & 97\% & Occasional cells & 0\% & p=.05 \\
\hline
p63/CD31 in normal vessels & 100\% & 0 & 0 \\
\hline
p63/CD31 in LVI & 95\% & Occasional cells & 0\% & p=.05 \\
\hline
p63/D2-40 in normal lymphatics & 100\% & 0 & 0 \\
\hline
p63/D2-40 in LVI & 97\% & Occasional cells & 0\% & p=.05 \\
\hline
\end{tabular}}
\end{table}
|
PMC3058877_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{COG id} & \textbf{Description} & \multicolumn{2}{|l|}{\textbf{Mature}} & \multicolumn{2}{|l|}{\textbf{Infant}} & \textbf{Metastat q- value} \\
\hline
& & \textbf{Mean abundance (\%)} & \textbf{stderr} & \textbf{Mean abundance (\%)} & \textbf{stderr} \\
\hline
COG0205 & 6-phosphofructokinase & 0.0017 & 0.0001 & 0.0006 & 0.0002 & 0.0313 \\
\hline
COG0358 & DNA primase (bacterial type) & 0.0024 & 0.0001 & 0.0008 & 0.0001 & 0.0072 \\
\hline
COG0507 & ATP-dependent exoDNAse (exonuclease V), alpha subunit - helicase superfamily I member & 0.0016 & 0.0001 & 0.0008 & 0.0001 & 0.0349 \\
\hline
COG0526 & Thiol-disulfide isomerase and thioredoxins & 0.0028 & 0.0002 & 0.0014 & 0.0002 & 0.0371 \\
\hline
COG0621 & 2-methylthioadenine synthetase & 0.0017 & 0.0001 & 0.0008 & 0.0002 & 0.0450 \\
\hline
COG0642 & Signal transduction histidine kinase & 0.0132 & 0.0009 & 0.0070 & 0.0004 & 0.0270 \\
\hline
COG0667 & Predicted oxidoreductases (related to aryl-alcohol dehydrogenases) & 0.0012 & 0.0001 & 0.0021 & 0.0001 & 0.0282 \\
\hline
COG0739 & Membrane proteins related to metalloendopeptidases & 0.0024 & 0.0001 & 0.0006 & 0.0001 & 0.0072 \\
\hline
COG0745 & Response regulators consisting of a CheY-like receiver domain and a winged-helix DNA-binding domain & 0.0076 & 0.0003 & 0.0051 & 0.0004 & 0.0352 \\
\hline
COG0747 & ABC-type dipeptide transport system, periplasmic component & 0.0011 & 0.0001 & 0.0027 & 0.0003 & 0.0352 \\
\hline
COG1113 & Gamma-aminobutyrate permease and related permeases & 0.0002 & 0.0001 & 0.0018 & 0.0003 & 0.0349 \\
\hline
COG1129 & ABC-type sugar transport system, ATPase component & 0.0013 & 0.0001 & 0.0028 & 0.0003 & 0.0492 \\
\hline
COG1145 & Ferredoxin & 0.0017 & 0.0001 & 0.0005 & 0.0002 & 0.0217 \\
\hline
COG1196 & Chromosome segregation ATPases & 0.0017 & 0.0001 & 0.0007 & 0.0001 & 0.0108 \\
\hline
COG1249 & Pyruvate/2-oxoglutarate dehydrogenase complex, dihydrolipoamide dehydrogenase (E3) component, and related enzymes & 0.0006 & 0.0001 & 0.0011 & 0.0001 & 0.0349 \\
\hline
COG1263 & Phosphotransferase system IIC components, glucose/maltose/N- acetylglucosamine-specific & 0.0012 & 0.0001 & 0.0031 & 0.0003 & 0.0313 \\
\hline
COG1475 & Predicted transcriptional regulators & 0.0025 & 0.0002 & 0.0014 & 0.0002 & 0.0435 \\
\hline
COG1595 & DNA-directed RNA polymerase specialized sigma subunit, sigma24 homolog & 0.0053 & 0.0004 & 0.0013 & 0.0003 & 0.0206 \\
\hline
COG1609 & Transcriptional regulators & 0.0030 & 0.0002 & 0.0092 & 0.0013 & 0.0424 \\
\hline
COG1629 & Outer membrane receptor proteins, mostly Fe transport & 0.0120 & 0.0016 & 0.0013 & 0.0007 & 0.0313 \\
\hline
COG1762 & Phosphotransferase system mannitol/fructose-specific IIA domain (Ntr-type) & 0.0004 & 0.0001 & 0.0017 & 0.0002 & 0.0293 \\
\hline
COG1961 & Site-specific recombinases, DNA invertase Pin homologs & 0.0059 & 0.0004 & 0.0018 & 0.0006 & 0.0345 \\
\hline
COG2204 & Response regulator containing CheY-like receiver, AAA-type ATPase, and DNA-binding domains & 0.0019 & 0.0002 & 0.0005 & 0.0002 & 0.0421 \\
\hline
COG2244 & Membrane protein involved in the export of O-antigen and teichoic acid & 0.0019 & 0.0001 & 0.0009 & 0.0001 & 0.0229 \\
\hline
COG2376 & Dihydroxyacetone kinase & 0.0002 & 0 & 0.0009 & 0.0001 & 0.0278 \\
\hline
COG2440 & Ferredoxin-like protein & 0 & 0 & 0.0002 & 0 & 0.0394 \\
\hline
COG2893 & Phosphotransferase system, mannose/fructose-specific component IIA & 0.0003 & 0.0001 & 0.0011 & 0.0001 & 0.0352 \\
\hline
COG3250 & Beta-galactosidase/beta-glucuronidase & 0.0056 & 0.0004 & 0.0023 & 0.0006 & 0.0435 \\
\hline
COG3451 & Type IV secretory pathway, VirB4 components & 0.0033 & 0.0001 & 0.0009 & 0.0003 & 0.0157 \\
\hline
COG3505 & Type IV secretory pathway, VirD4 components & 0.0029 & 0.0001 & 0.0010 & 0.0003 & 0.0278 \\
\hline
COG3525 & N-acetyl-beta-hexosaminidase & 0.0016 & 0.0002 & 0.0004 & 0.0001 & 0.0352 \\
\hline
COG3537 & Putative alpha-1,2-mannosidase & 0.0020 & 0.0003 & 0.0002 & 0.0002 & 0.0352 \\
\hline
COG3711 & Transcriptional antiterminator & 0.0004 & 0.0001 & 0.0020 & 0.0003 & 0.0339 \\
\hline
COG3712 & Fe2+-dicitrate sensor, membrane component & 0.0023 & 0.0003 & 0 & 0 & 0.0280 \\
\hline
COG4206 & Outer membrane cobalamin receptor protein & 0.0021 & 0.0003 & 0.0003 & 0.0001 & 0.0313 \\
\hline
COG4771 & Outer membrane receptor for ferrienterochelin and colicins & 0.0039 & 0.0005 & 0.0006 & 0.0003 & 0.0366 \\
\hline
\end{tabular}}
\end{table}
|
PMC2661018_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Subtype} & \textbf{Negative n (\%)} & \textbf{Positive n (\%)} & \textbf{Total n (\%)} \\
\hline
Luminal & 21 (55.3\%) & 17 (44.7\%) & 38 (100\%) \\
\hline
Basal & 0 (.0\%) & 1 (100.0\%) & 1 (100\%) \\
\hline
HER2 & 7 (43.8\%) & 9 (56.2\%) & 16 (100\%) \\
\hline
Null & 3 (75.0\%) & 1 (25.0\%) & 4 (100\%) \\
\hline
Total & 31 (52.5\%) & 28 (47.5\%) & 59 (100.0\%) \\
\hline
\end{tabular}}
\end{table}
|
PMC3109576_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Condition} & \textbf{Qv (g SA/L.h)} & \textbf{Qp (mg SA/g cell mass.h)} & \textbf{Y(X/S) (g/100 g)} & \textbf{Y(P/S) (g/100 g)} \\
\hline
Wild type & 0.01 & 8.83 & 25 & 2.65 \\
\hline
Recombinant & 0.08 & 26.31 & 33.25 & 21 \\
\hline
Fold & 8 & 2.97 & 1.33 & 7.92 \\
\hline
\end{tabular}}
\end{table}
|
PMC4490670_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\multicolumn{11}{|l|}{amplitude(uV)} \\
\hline
& a-wave & p value & b-wave & p value & on-PhNR & p value & d-wave & p value & off-PhNR & p value \\
\hline
pre & 21.35$\pm$7.08 & 0.48470677 & 43.35$\pm$14.14 & 0.11985184 & 28.3$\pm$13.58 & 0.00017395 & 36.8$\pm$14.21 & 0.07105886 & 32.75$\pm$9.37 & 0.26110339 \\
\hline
post & 20.5$\pm$5.09 & & 37.55$\pm$17.58 & & 18.1$\pm$10.25 & & 31.65$\pm$8.62 & & 29.5$\pm$7.83 \\
\hline
\multicolumn{11}{|l|}{latency(msec)} \\
\hline
& a-wave & p value & b-wave & p value & on-PhNR & p value & d-wave & p value & off-PhNR & p value \\
\hline
pre & 21.45$\pm$3.27 & 2.47E-08 & 37.95$\pm$3.93 & 5.27E-11 & 58.95$\pm$6.9 & 5.9241E-10 & 24.15$\pm$3.0 & 2.5221E-07 & 41.85$\pm$3.44 & 2.72E-08 \\
\hline
post & 30.6$\pm$4.92 & & 53.55$\pm$6.33 & & 77.7$\pm$9.92 & & 32.55$\pm$4.16 & & 53.1$\pm$5.51 \\
\hline
\multicolumn{11}{|l|}{amplitude(uV)} \\
\hline
& OP1 & p value & OP2 & p value & OP3 & p value & OP4 & p value & OP5 & p value \\
\hline
pre & 7.07$\pm$3.65 & 0.17859439 & 8.6$\pm$3.62 & 4.0256E-06 & 4.47$\pm$2.69 & 0.00639687 & 8$\pm$2.76 & 5.7025E-05 & 6.98$\pm$3.35 & 5.4395E-05 \\
\hline
post & 4.65$\pm$7.42 & & 3.87$\pm$1.85 & & 2.4$\pm$1.35 & & 4.13$\pm$2.62 & & 2.44$\pm$1.38 \\
\hline
\multicolumn{11}{|l|}{latency(msec)} \\
\hline
& OP1 & p value & OP2 & p value & OP3 & p value & OP4 & p value & OP5 & p value \\
\hline
pre & 23.75$\pm$3.81 & 6.5995E-06 & 31.5$\pm$2.67 & 5.0376E-07 & 38.53$\pm$2.87 & 2.8302E-07 & 21.15$\pm$2.48 & 1.8191E-10 & 28.8$\pm$5.44 & 1.2112E-05 \\
\hline
post & 33.7$\pm$6.05 & & 43.26$\pm$7.16 & & 49.8$\pm$5.05 & & 29.3$\pm$4.15 & & 39.5$\pm$4.15 \\
\hline
\multicolumn{11}{|l|}{temperature (degrees centigrade)} \\
\hline
& & p value \\
\hline
pre & 33.2$\pm$1.28 & 4.1491E-08 \\
\hline
post & 29.45$\pm$1.65 \\
\hline
\end{tabular}}
\end{table}
|
PMC4806841_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Class} & \textbf{Total} \\
\hline
Synonymous SNPs & 11,155 \\
\hline
\multicolumn{2}{|l|}{Non-synonymous SNPs} \\
\hline
Missense type & 11,107 \\
\hline
Non-sense type & 109 \\
\hline
\multicolumn{2}{|l|}{Coding-region Indels} \\
\hline
In-frame Indels & 172 \\
\hline
Frame-shifting Indels & 200 \\
\hline
\end{tabular}}
\end{table}
|
PMC3534380_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Risk of dissatisfaction} & \textbf{Public (\%)} & \textbf{Private (\%)} & \textbf{All (\%)} \\
\hline
Properly identified specimen & 3/10(30.0) & 1/4(25.0) & 4/14(28.6) \\
\hline
Clear and accurate test request & 4/10 (40.0) & 2/4(50.0) & 6/14(42.9) \\
\hline
Properly collected and transported specimen & 3/10(30.0) & 1/4(25.0) & 4/14(28.6) \\
\hline
Availability of equipment & 4/10 (40.0) & 1/4(25.0) & 5/14(35.7) \\
\hline
Communication between laboratories & 4/10 (40.0) & 2/4(50.0) & 6/14(42.9) \\
\hline
Timely results feed back to the sending laboratory & 1/10(10.0) & 1/4(25.0) & 2/14(14.5) \\
\hline
\end{tabular}}
\end{table}
|
PMC2518553_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Average measures} & \textbf{Intraclass correlation} & \multicolumn{2}{|l|}{\textbf{95\% confidence interval}} & \multicolumn{4}{|l|}{\textbf{F test with true value 0}} \\
\hline
& & \textbf{Lower bound} & \textbf{Upper bound} & \textbf{F} & \textbf{Df1} & \textbf{Df2} & \textbf{P} \\
\hline
Input delay & .881 & .751 & .949 & 8.34 & 19 & 38 & $<$.001 \\
\hline
Output gain & .914 & .820 & .963 & 11.75 & 19 & 38 & $<$.001 \\
\hline
Damping constant & .866 & .717 & .943 & 8.34 & 19 & 38 & $<$.001 \\
\hline
Reference value & .824 & .628 & .925 & 5.50 & 19 & 38 & $<$.001 \\
\hline
\end{tabular}}
\end{table}
|
PMC5662710_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Metrics} & \textbf{stroma} & \textbf{Benign hyperplasia} & \textbf{intraepithelial neoplasia} & \textbf{carcinoma} \\
\hline
Jaccard-similarity-coefficient & 80 & 76 & 75 & 82 \\
\hline
Dice-similarity-coefficient & 87 & 86 & 86 & 89 \\
\hline
False positive rates & 05 & 07 & 05 & 04 \\
\hline
False negative rates & 15 & 18 & 20 & 14 \\
\hline
\end{tabular}}
\end{table}
|
PMC5893871_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Yes} & \textbf{No} & \textbf{Unclear} & \textbf{Comments} \\
\hline
1. Was the randomisation procedure adequate? & ☐ & ☐ & ☐ \\
\hline
2. Was the treatment allocation adequately concealed? & ☐ & ☐ & ☐ \\
\hline
3. Were participants blinded to the intervention? & ☐ & ☐ & ☐ \\
\hline
4. Were physicians blinded to the intervention? & ☐ & ☐ & ☐ \\
\hline
5. Were outcome assessors blinded to the intervention? & ☐ & ☐ & ☐ \\
\hline
6. Incomplete outcome data: Is the attrition rate $<$15 \%? & ☐ & ☐ & ☐ \\
\hline
7. Are all pre-specified outcomes of interest reported in the pre-specified way? & ☐ & ☐ & ☐ \\
\hline
8. Was intention-to-treat analysis used? & ☐ & ☐ & ☐ \\
\hline
9. Were the treatment and control group similar at baseline? & ☐ & ☐ & ☐ \\
\hline
\end{tabular}}
\end{table}
|
PMC5084436_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Profiles} & \textbf{Characterization of the cluster defining the profile} \\
\hline
Professional & contacts at work have highest median as compared to other locations: m11 = max {m1i:i = 1,…,6} \\
\hline
School & contacts at school have highest median m22 = max {m2i:i = 1,…,6} \\
\hline
Leisure & contacts during leisure activities have highest median: m33 = max {m3i:i = 1,…,6} \\
\hline
Big home & contacts at home have highest median: m44 = max {m4i:i = 1,…,6} \\
\hline
Other place & contacts in ‘‘other place’’ have highest median: m55 = max {m5i:i = 1,…,6} \\
\hline
Mixed & contacts in more than one location have a median higher than the remaining cluster: m6i.m7i for at least two i = 1,…,6. \\
\hline
Low contacts & The remaining cluster \\
\hline
\end{tabular}}
\end{table}
|
PMC2691957_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Groups} & \multicolumn{2}{|l|}{\textbf{LDH level IU/L}} & \textbf{Percent of changing} \\
\hline
& \textbf{Before treatment} & \textbf{After treatment} \\
\hline
Doxorubicin 15 mg./kg & 578.8 $\pm$ 72.3 & 4328.1 $\pm$ 209.5 ††** & 647\% \\
\hline
Doxo. + Vit E 100 mg./kg & 585.1 $\pm$ 51.4 & 1494.9 $\pm$ 55.1†† ** & 155\% \\
\hline
Doxo. + Telmisartan 1 mg./kg & 570.4 $\pm$ 31.9 & 3108.5 $\pm$ 248.9 ††** & 444\% \\
\hline
\end{tabular}}
\end{table}
|
PMC3483230_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\multicolumn{2}{|l|}{\textbf{Findings}} & \multicolumn{2}{|l|}{\textbf{Patients}} \\
\hline
& & \textbf{\#} & \textbf{\% 1} \\
\hline
Respiratory & Pneumonia & 69 & 63.9 \\
\hline
& Pleural effusion & 12 & 11.1 \\
\hline
& Exacerbated COPD/Asthma & 24 & 22.2 \\
\hline
& Arterial blood pH,7.35 or .7.45 & 58 & 53.7 \\
\hline
& Respiratory rate .25/min & 30 & 27.8 \\
\hline
& Sp02 ,94\% or PaO2,8 Kpa & 22 & 20.4 \\
\hline
Cardiovascular & Acute or exacerbated chronic heart failure & 7 & 6.5 \\
\hline
& Myo/pericarditis & 2 & 1.9 \\
\hline
& Arrhythmia/electrocardiographic alterations & 15 & 13.9 \\
\hline
& Severe dehydration & 22 & 20.4 \\
\hline
& Hearth rate .110/min & 29 & 26.9 \\
\hline
& Blood pressure: systolic ,90 mm Hg or diastolic \#60 mm Hg & 17 & 15.7 \\
\hline
& Elevated myocardial enzymes & 18 & 16.7 \\
\hline
Renal & Acute or exacerbated chronic renal failure/Dyalisis & 15 & 13.9 \\
\hline
& Elevated blood urea nitrogen & 15 & 13.9 \\
\hline
& Electrolyte imbalance & 9 & 8.3 \\
\hline
Hepatic & Acute hepatitis or exacerbated chronic liver disease & 6 & 5.6 \\
\hline
Neurological & Decreased consciousness & 5 & 4.6 \\
\hline
Haematological & WBC ,4,000 or .12,000/mL & 31 & 28.7 \\
\hline
& HGB ,10 g/dL & 10 & 9.3 \\
\hline
Gastrointestinal & Severe vomit/Inability to maintain oral intake & 13 & 12.0 \\
\hline
Sepsis & & 3 & 2.8 \\
\hline
\$1 finding of moderate intermediate clinical severity & & 100 & 92.6 \\
\hline
\$1 finding of moderate intermediate clinical severity, or \$1 risk-factor 2 & & 105 & 97.2 \\
\hline
\end{tabular}}
\end{table}
|
PMC3419232_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{5}{|l|}{\textbf{Female respondents (n = 355)}} & \multicolumn{5}{|l|}{\textbf{Male respondents (n = 488)}} \\
\hline
& \textbf{1} & \textbf{2} & \textbf{3} & \textbf{4} & \textbf{5} & \textbf{1} & \textbf{2} & \textbf{3} & \textbf{4} & \textbf{5} \\
\hline
1. PTSD score & – & 0.55** & 0.34** & 0.50** & 0.10* & – & 0.60** & 0.37** & 0.59** & 0.39** \\
\hline
2. Depression score & & – & 0.53** & 0.41** & 0.07 & & – & 0.49** & 0.44** & 0.23* \\
\hline
3. Suicide risk & & & – & 0.34** & 0.07 & & & – & 0.32** & 0.08 \\
\hline
4. Trauma exposure & & & & – & 0.44** & & & & – & 0.49** \\
\hline
5. Duration abductions & & & & & – & & & & & – \\
\hline
\end{tabular}}
\end{table}
|
PMC4348469_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{|l|}{\textbf{S1}} & \multicolumn{3}{|l|}{\textbf{S2}} & \multicolumn{3}{|l|}{\textbf{S3}} \\
\hline
& \textbf{With FNS} & \textbf{Without FNS} & \textbf{P-value} & \textbf{With FNS} & \textbf{Without FNS} & \textbf{P-value} & \textbf{With FNS} & \textbf{Without FNS} & \textbf{P-value} \\
\hline
Average Max AP Trunk Angle (°) & 18.88 $\pm$ 3.23 & 24.78 $\pm$ 2.62 & 0.03* & 9.92 $\pm$ 2.24 & 16.1 $\pm$ 1.76 & 0.005* & 16.23 $\pm$ 2.52 & 21.60 $\pm$ 3.21 & 0.08 \\
\hline
Average Return Time to Erect (s) & 0.45 $\pm$ 0.07 & 0.65 $\pm$ 0.13 & 0.05 & 0.20 $\pm$ 0.05 & 1.18 $\pm$ 1.07 & 0.18 & 0.73 $\pm$ 0.37 & 3.94 $\pm$ 1.23 & 0.007* \\
\hline
URS Median & 1 & 0 & 0.1 & 3 & 2 & 0.1 & 1 & 1 & 1 \\
\hline
\end{tabular}}
\end{table}
|
PMC5848592_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& & \textbf{CBP statistics: Punctual vs Iterative} & \textbf{GLM statistics: Punctual context} & \textbf{GLM statistics: Iterative context} \\
\hline
1 & Now position (Time: 600–800 ms, Frequency: 60–80 Hz) & tsum = 798.09, p = 0.012, S = 535 & t = 3.145, p = 0.002 & t = 0.017, p = 0.986 \\
\hline
2 & Verb position (Time: 600–800 ms, Frequency: 60–80 Hz) & tsum = 614.372, p = 0.018, S = 419 & t = 3.296, p = 0.001 & t = −0.044, p = 0.965 \\
\hline
\end{tabular}}
\end{table}
|
PMC4395362_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Location} & \textbf{Trial(s)} & \textbf{df1} & \textbf{df2a} & \textbf{F statistic} & \textbf{p-value} & \textbf{Difference b (degrees)} \\
\hline
Inland & All trials & 1 & 119,998 & 740 & $\leq$ 0.001 & 11.11 \\
\hline
& Trial A & 1 & 39,998 & 0 & 0.963 & 0.03 \\
\hline
& Trial B & 1 & 39,998 & 729 & $\leq$ 0.001 & 22.14 \\
\hline
& Trial C & 1 & 39,998 & 144 & $\leq$ 0.001 & 6.98 \\
\hline
Shoreline & All trials & 1 & 119,998 & 5048 & $\leq$ 0.001 & 30.34 \\
\hline
& Trial A & 1 & 39,998 & 1756 & $\leq$ 0.001 & 31.69 \\
\hline
& Trial B & 1 & 39,998 & 1772 & $\leq$ 0.001 & 35.13 \\
\hline
& Trial C & 1 & 39,998 & 1370 & $\leq$ 0.001 & 24.09 \\
\hline
Over Water & All trials & 1 & 119,998 & 17,098 & $\leq$ 0.001 & 51.84 \\
\hline
& Trial A & 1 & 39,998 & 7153 & $\leq$ 0.001 & 57.67 \\
\hline
& Trial B & 1 & 39,998 & 5292 & $\leq$ 0.001 & 58.74 \\
\hline
& Trial C & 1 & 39,998 & 4944 & $\leq$ 0.001 & 41.84 \\
\hline
\end{tabular}}
\end{table}
|
PMC6114834_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Administrator at regional/county level n = 20 (\%)} & \textbf{Health care personnel at health centers n = 315 (\%)} \\
\hline
\multicolumn{3}{|l|}{Sex} \\
\hline
Female & 16 (80.0) & 247(78.4) \\
\hline
Male & 4 (20.0) & 58 (18.4) \\
\hline
Missing & 0 & 10 (3.2) \\
\hline
\multicolumn{3}{|l|}{Work position} \\
\hline
Administrator & 14 (70.0) \\
\hline
Economist & 3 (15.0) \\
\hline
Manager & 1 (5.0) \\
\hline
Investigator & 1 (5.0) \\
\hline
Physician & & 70 (22.2) \\
\hline
Nurse/community nurse & & 217 (69.0) \\
\hline
Head of unit / Manager & & 42 (13.3) \\
\hline
Missing & 1 (5.0) & 26 (8.3) \\
\hline
\multicolumn{3}{|l|}{Country of birth} \\
\hline
Sweden & 16 (80.0) & 286 (90.8) \\
\hline
Europe (except Sweden) & 3 (15.0) & 16 (5.1) \\
\hline
Outside Europe & & 9 (2.9) \\
\hline
Missing & 1 (5.0) & 4 (1.3) \\
\hline
\multicolumn{3}{|l|}{Special training in relation to migrants’ health} \\
\hline
Yes & 4 (20.0) & 53 (16.8) \\
\hline
No & 16 (80.0) & 255 (81.0) \\
\hline
Missing & & 7 (2.2) \\
\hline
\multicolumn{3}{|l|}{Experience of similar work abroad} \\
\hline
Yes & & 55 (17.5) \\
\hline
In a European country & & 27 (49.1) \\
\hline
In a country outside Europe & & 26 (47.3) \\
\hline
Missing & & 2 (3.6) \\
\hline
No & 17 (85.0) & 255 (81.0) \\
\hline
Missing & 3 (15.0) & 5 (1.6) \\
\hline
\multicolumn{3}{|l|}{Number of years in the present or similar position} \\
\hline
1–5 years & 10 (50.0) & 161 (51.1) \\
\hline
6–10 years & 6 (30.0) & 51 (16.2) \\
\hline
More than 10 years & 3 (15.0) & 45 (14.3) \\
\hline
Missing & 1 (5.0) & 58 (18.4) \\
\hline
\end{tabular}}
\end{table}
|
PMC6199803_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Treatment Group} & \textbf{Time Post-Exposure} & \textbf{AII} & \textbf{BI} & \textbf{TBI} & \textbf{BHH} \\
\hline
Gr20 & 7 day & - & 0.17 (1/6) & 1.7 (6/6) & 1.0 (5/6) \\
\hline
Gr5 & 7 day & - & - & 1.0 (5/6) & - \\
\hline
Gr1 & 7 day & - & - & - & - \\
\hline
CB & 7 day & - & - & 0.5 (3/6) & 0.17 (1/6) \\
\hline
Gr20 & 1 month & 0.17 (1/6) & - & 0.7 (4/6) & 0.7 (4/6) \\
\hline
Gr5 & 1 month & - & - & 0.7 (2/6) & 0.5 (3/6) \\
\hline
Gr1 & 1 month & - & - & - & - \\
\hline
CB & 1 month & - & - & - & - \\
\hline
Gr20 & 2 months & - & - & 0.7 (4/6) & 0.83 (5/6) \\
\hline
Gr5 & 2 months & 0.3 (2/6) & - & - & 0.5 (3/6) \\
\hline
Gr1 & 2 months & - & - & - & - \\
\hline
CB & 2 months & - & - & - & - \\
\hline
\end{tabular}}
\end{table}
|
PMC4915050_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Source} & \multicolumn{2}{|l|}{\textbf{dChip}} & \multicolumn{2}{|l|}{\textbf{MAS 5.0}} & \multicolumn{2}{|l|}{\textbf{RMA}} & \multicolumn{2}{|l|}{\textbf{GCRMA-EB}} \\
\hline
& \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} \\
\hline
Biological variation & 0.431 & 0.304 & 0.292 & 0.300 & 0.393 & 0.306 & 0.310 & 0.292 \\
\hline
Labeling variation & 0.206 & 0.230 & 0.136 & 0.198 & 0.221 & 0.224 & 0.147 & 0.192 \\
\hline
Residual error & 0.363 & 0.274 & 0.572 & 0.311 & 0.386 & 0.272 & 0.543 & 0.298 \\
\hline
\end{tabular}}
\end{table}
|
PMC1232851_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Domain} & \textbf{Criteria} \\
\hline
Qualification & At least 10 years of formal education (equivalent to GCSE) \\
\hline
Experience & Socio-demographic background and life experiences similar to that of the target population \\
\hline
& Emotional maturity/range of life experience \\
\hline
Personal attributes & Willingness to learn new skills \\
\hline
& Good interpersonal skills \\
\hline
& Ability to relate to mothers and their families \\
\hline
& Ability to maintain a balance between home and work responsibilities \\
\hline
& Trustworthy, empathetic, respectful and enthusiastic \\
\hline
Knowledge/understanding & Some understanding of mother and child health issues \\
\hline
Other requirements & Fluent in local language \\
\hline
& Able to move in the community freely including if the target population is slightly far off from her place of residence \\
\hline
\end{tabular}}
\end{table}
|
PMC4793537_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Bacteria isolates} & \textbf{N} & \textbf{GEN n(\%)} & \textbf{CRX n(\%)} & \textbf{CHLO n(\%)} & \textbf{CTR n(\%)} & \textbf{CTX n(\%)} & \textbf{AMP n(\%)} & \textbf{TET n(\%)} & \textbf{COT n(\%)} & \textbf{PEN n(\%)} & \textbf{FLX n(\%)} & \textbf{ERY n(\%)} \\
\hline
\\
\hline
Salmonella spp & 8 & - & - & 5(62.5) & 8(100.0) & 8(100.0) & 0(0.0) & 0(0.0) & 0(0.0) & - & - & - \\
\hline
Klebsiella spp & 12 & 4(33.3) & 1(8.3) & 5(41.7) & 11(91.7) & 11(91.7) & 0(0.0) & 1(8.3) & 0(0.0) & - & - & - \\
\hline
Escherichia coli & 6 & 4(66.7) & 4(66.7) & 2(33.3) & 4(66.7) & 4(66.7) & 2(33.3) & 1(16.7) & 2(33.3) & - & - & - \\
\hline
Acinetobacter spp & 2 & 2(100.0) & 0(0.0) & 0(0.0) & 2(100) & 2(100.0) & 0(0.0) & 0(0.0) & 0(0.0) & - & - & - \\
\hline
Pseudomonas aeruginosa & 3 & 1(33.3) & - & - & 1(33.3) & 1(33.3) & - & - & - & - & - & - \\
\hline
Coagulase negative Staphylococci & 25 & 18(72.0) & 14(56.0) & - & - & - & 1(4.0) & 6(24.0) & 5(20.0) & 1(4.0) & 10(40.0) & 13(52.0) \\
\hline
Coagulase positive Staphylococci & 28 & 12(42.9) & 16(57.1) & - & - & - & 1(3.6) & 2(25) & 2(7.1) & 1(3.6) & 8(28.6) & 10(35.7) \\
\hline
\end{tabular}}
\end{table}
|
PMC3598494_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Species} & \textbf{Date} & \textbf{Tstart [°C]} & \textbf{WR [K·h−1]} & \textbf{Texp [°C]} & \textbf{Tc [°C]} & \textbf{LT5 [°C]} & \textbf{T [°C]} & \textbf{PPFD} \\
\hline
Rhododendron ferrugineum & 9 August 2012 & 30 & 6.5 & 43 & 44 & 46 & 11 & 261 \\
\hline
Rh. ferrugineum & 9 August 2012 & 30 & 7.5 & 45 & 44 & 46 & 11 & 261 \\
\hline
Senecio incanus & (10) 11 July 2013 & 30 & 7 & 44 & 45 & 47 & (17) 19 & (732) 1047 \\
\hline
S. incanus & (10) 11 July 2013 & 30 & 8 & 46 & 45 & 47 & (17) 19 & (732) 1047 \\
\hline
Ranunculus. glacialis & (10) 11 August 2013 & 25 & 8 & 41 & 43 & 44 & (5) 8 & (1351) 1501 \\
\hline
Ra. glacialis & (10) 11 August 2013 & 25 & 9 & 43 & 43 & 44 & (5) 8 & (1351) 1501 \\
\hline
\end{tabular}}
\end{table}
|
PMC4407927_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Gene symbol} & \textbf{Direction} & \textbf{Primer sequence} & \textbf{Amplicon size} \\
\hline
AMR & Forward & GTGCATGCCATTGCCTAGCTGA & 78 \\
\hline
& Reverse & TCATTTCCGGTGTGGCTTGGCA \\
\hline
Bax & Forward & CCAGGACGCATCCACCAAGAAGC & 136 \\
\hline
& Reverse & TGCCACACGGAAGAAGACCTCTCG \\
\hline
Bcl-2 & Forward & GAGGCTGGGATGCCTTTGTGGA & 89 \\
\hline
& Reverse & GCTGAGCAGCGTCTTCAGAGA \\
\hline
CyD1 & Forward & ATCAAGTGTGACCCGGACTG & 216 \\
\hline
& Reverse & GCCACTACTTGGTGACTCCC \\
\hline
HSF1 & Forward & CCATGAAGCACGAGAACGAG & 117 \\
\hline
& Reverse & ACTGCACCAGTGAGATCAGGA \\
\hline
PAcP & Forward & CGGGATCCTGGTGATATTGCT & 70 \\
\hline
& Reverse & CCGATACACGTCTCTCTGCC \\
\hline
p21 & Forward & ACATCTCAGGGCCGAAAACG & 78 \\
\hline
& Reverse & CTTGCAGAAGACCAATCGGC \\
\hline
TM & Forward & GATCTCCATTGCCAGCCT & 140 \\
\hline
& Reverse & CACGTGCTGCAGTACTACCT \\
\hline
GAPDH & Forward & TGGAAGGACTCATGACCACA & 160 \\
\hline
& Reverse & TTCAGGTCAGGGATGACCTT \\
\hline
\end{tabular}}
\end{table}
|
PMC4440734_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& & \multicolumn{3}{|l|}{\textbf{12:00}} \\
\hline
& & \textbf{Max} & \textbf{Middle} & \textbf{Min} \\
\hline
14:00 & Max & 0.993 & 0.977 & 0.986 \\
\hline
& Middle & 0.966 & 0.997 & 0.957 \\
\hline
& Min & 0.993 & 0.972 & 0.991 \\
\hline
\end{tabular}}
\end{table}
|
PMC5750798_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Gene} & \textbf{Primer} & \textbf{Sequence (5’-3’)} & \textbf{Number of CpGs} \\
\hline
FOXP3 & forward & Biotin-AGTTTGGTTTGTGGGAAATTGTT \\
\hline
& reverse & ACCCTATTATCTCATTAATACCTCTCA \\
\hline
& Sequence 1 & ATAAAAACAAAATTATTTTTAATA & 1 \\
\hline
& Sequence 2 & AAATTATTAAAAAAAAAAAATCTAC & 4 \\
\hline
FOXP3 Enhancer & forward & ATGAAGGGGAGGAGGAAG \\
\hline
& reverse & Biotin-CCTCCAACTCCACCATAAC \\
\hline
& Sequence 1 & GAGGAAGAGGAGGTT & 4 \\
\hline
& Sequence 2 & GGGTTTTATTTGGTTTTTATATT & 7 \\
\hline
\end{tabular}}
\end{table}
|
PMC4928917_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Prot. name PDB ID basic(acid)} & \textbf{Protein family} & \textbf{Resolution basic(acid)} & \textbf{H-bond residues} & \textbf{H-bond distances basic(acid)} & \textbf{p/p interactions residues} & \textbf{p/p interactions distances basic(acid)} \\
\hline
3J27@ (1URZ) & Membrane fusion protein Flavivirus Class II & 3.5 Å(2.7 Å) & H317*-S396* & 3.3 Å(14.0 Å) & H261-W19w H7w-W212 & 3.6 Åz (N/Aw) 2.8 Åz (N/Aw) \\
\hline
3N43(N/Aw) & Membrane fusion protein Alphavirus Class II & 2.6 Å(N/Aw) & H170*,w-S57* & 2.9 Å(N/Aw) & H73w-W89 & 3.6 Åz (N/Aw) \\
\hline
2J6J(2CMZ) & Membrane fusion protein Rhabdovirus Class III & 3 Å(2.4 Å) & H407*-S84* & 3.4 Å(32.2 Å) & H33-F189 & 3.9 Åz (11.2 Å) \\
\hline
OmpG 2IWW(2IWV) & Bacterial membrane protein & 2.3 Å(2.7 Å) & H231-S218 & 2.9 Å(9.9 Å) & H261-F233 & 4.5 Å (7,9 Å) \\
\hline
M-Ficolin 2JHM(2JHH) & Human soluble protein & 1.52 Å(1.7 Å) & H268-S270 H222-S257 & 3.5 Å(8.7 Å) 3.6 Å(12.7 Å) & H222-W249 H255-Y251 H255-Y283 & 3.6 Å (3.3 Å) 4.0 Å (10.5 Å) 3.6 Å (17.5 Å) \\
\hline
\end{tabular}}
\end{table}
|
PMC4518280_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Variable/Areas Women} & \textbf{Formal (n = 153)} & \textbf{Informal (n = 297)} & \textbf{Total (n = 450)} & \textbf{P} \\
\hline
\\
\hline
Fruits, n (\%) & & & & 0.310c \\
\hline
Daily & 87 (56.9) & 184 (62.0) & 271 (60.2) \\
\hline
Others & 66 (43.1) & 113 (38.0) & 179 (39.8) \\
\hline
Vegetables, n (\%) & & & & 0.604c \\
\hline
Daily & 52 (34.2) & 110 (37.0) & 162 (36.1) \\
\hline
Others & 100 (65.8) & 187 (63.0) & 287 (63.9) \\
\hline
K (mg/day), median (IQR) & 2453.6 (1801.4–3176.1) & 2592.3 (1877.1–3380.5) & 2562.6 (1838.0–3321.9) & 0.298b \\
\hline
Recommendation K intake, n (\%) & & & & 0.066c \\
\hline
$\geq$ 3510 mg/day & 24 (15.7) & 69 (23.3) & 93 (20.7) \\
\hline
$<$ 3510 mg/day & 129 (84.3) & 227 (76.7) & 356 (79.3) \\
\hline
Self-reported SALT intake, n (\%) & & & & 0.262a \\
\hline
Not consume & 6 (3.9) & 4 (1.3) & 10 (2.2) \\
\hline
Low & 81 (52.9) & 148 (49.8) & 229 (50.9) \\
\hline
Normal & 64 (41.8) & 141 (47.5) & 205 (45.6) \\
\hline
Enough/Add salt & 2 (1.3) & 4 (1.3) & 6 (1.3) \\
\hline
Na (mg/day), median (IQR) & 2522.4 (1638.2–4124.2) & 3243.4 (1950.0–5304.1) & 3019.8 (1786.8–4745.7) & 0.001b \\
\hline
Recommendation Na (mg/day), n (\%) & & & & 0.030c \\
\hline
$<$ 2000 & 55 (35.9) & 77 (26.0) & 132 (29.4) \\
\hline
$\geq$ 2000 & 98 (64.1) & 219 (74.0) & 317 (70.6) \\
\hline
\end{tabular}}
\end{table}
|
PMC6085717_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{CTS grade} & \textbf{Mild (n = 11)} & \textbf{Moderate (n = 55)} & \textbf{Total (n = 66)} & \textbf{P-value} \\
\hline
Age, years & 46[15] & 50[13] & 50[13] & 0.67 \\
\hline
Sex, F/M & 11/0 & 39/16 & 50/16 & 0.05 \\
\hline
Bilat./unilat. & 2/9 & 26/29 & 28/38 & 0.10 \\
\hline
ENeG SCV, m/s & 36[7] & 30[6] & 31[6] & 0.001 \\
\hline
ENeG SNAP, $\mu$V & 12[9] & 5[5] & 6[7] & 0.03 \\
\hline
ENeG DML, ms & 3.9[0.3] & 5.3[1.0] & 5.0[1.2] & $<$ 0.001 \\
\hline
SSS, score & 2.72[1.4] & 2.45[0.78] & 2.55[0.73] & 0.34 \\
\hline
SWM, no.of filament & 18[1] & 18[2] & 18[2] & 0.96 \\
\hline
\end{tabular}}
\end{table}
|
PMC5721389_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Model} & \textbf{WAIC} & \textbf{WAIC SE} & \textbf{$\Delta$ WAIC} \\
\hline
JC & 27548.3 & 92.0207 & 0 \\
\hline
SD & 27571.1 & 92.7548 & 22.8124 \\
\hline
TD & 27741.6 & 93.5845 & 193.243 \\
\hline
TSW & 27749.5 & 93.3275 & 201.18 \\
\hline
SW & 28072.5 & 87.9986 & 524.197 \\
\hline
\end{tabular}}
\end{table}
|
PMC5993323_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Reported motif} & \textbf{Dennis} & \textbf{Ozsolak} \\
\hline
AAAA/TTTT & 37 & 36 \\
\hline
AAAT & 26 & 28 \\
\hline
AATA & 7 & 6 \\
\hline
ATAA & 5 & 4 \\
\hline
GAAA & 37 & 38 \\
\hline
ATTA & 2 & 8 \\
\hline
TATA & 1 & 1 \\
\hline
AATT & 6 & 19 \\
\hline
ATAT & 2 & 6 \\
\hline
AGAA & 37 & 34 \\
\hline
AAGT & 28 & 22 \\
\hline
CGCG & 4 & 0 \\
\hline
TGGA & 32 & 39 \\
\hline
GCGC & 9 & 1 \\
\hline
CCCG/CGGG & 13 & 4 \\
\hline
for CGGC/GCCG & 4 & 8 \\
\hline
are GAAA/TTTC & 40 & 40 \\
\hline
CCGC/GCGG & 10 & 4 \\
\hline
\end{tabular}}
\end{table}
|
PMC3213122_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Term Category \#} & \textbf{Job title} & \textbf{\# of participants interviewed} \\
\hline
These 1 & Laboratory Manager & 3 \\
\hline
2 & Transfusion Safety Officer & 2 \\
\hline
blood 3 & Lab Technologist (Blood Bank) & 9 \\
\hline
to 4 & Physicians - Blood Bank & 4 \\
\hline
phy- 5 & Physicians - who use blood products & 7 \\
\hline
physi- 6 & Hospital Administration & 4 \\
\hline
but 7 & Hospital PR & 1 \\
\hline
CEOs, 8 & Hospital Risk Management & 2 \\
\hline
Within 9 & Blood Suppliers (CBS, Hema-Quebec) & 9 \\
\hline
11 & MoH (Provincial) & 2 \\
\hline
we blood 13 & Recipients of blood products & 2 \\
\hline
11 & Total & 45 \\
\hline
\end{tabular}}
\end{table}
|
PMC3223866_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Variable} & \multicolumn{4}{|l|}{\textbf{Total Sample}} & \multicolumn{4}{|l|}{\textbf{Public Sector}} & \multicolumn{4}{|l|}{\textbf{Private Sector}} \\
\hline
& \textbf{M} & \textbf{SD} & \textbf{2} & \textbf{3} & \textbf{M} & \textbf{SD} & \textbf{2} & \textbf{3} & \textbf{M} & \textbf{SD} & \textbf{2} & \textbf{3} \\
\hline
1. CWB & 1.73 & 0.67 & & & 1.67 & 0.69 & & & 1.78 & 0.66 \\
\hline
2. Envy & 2.32 & 0.89 & 0.23 ** & & 2.17 & 0.90 & 0.26 ** & & 2.45 & 0.86 & 0.19 * \\
\hline
3. LMX & 2.80 & 0.63 & −0.35 ** & −0.27 ** & 2.86 & 0.64 & −0.38 ** & −0.25 ** & 2.76 & 0.62 & −0.31 ** & −0.27 ** \\
\hline
\end{tabular}}
\end{table}
|
PMC6068656_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Gene symbol} & \textbf{C vs. MH1} & \textbf{C vs. MH2} & \textbf{C vs. SH1} & \textbf{C vs. SH2} & \textbf{C vs. SHW1} & \textbf{C vs. SHW2} \\
\hline
AMR & p = 0.004 & p = 0.001 & & & p = 0.001 & p = 0.008 \\
\hline
Bax & p = 0.048 & p = 0.000 & p = 0.000 & & p = 0.000 & p = 0.000 \\
\hline
Bcl-2 & & p = 0.000 & p = 0.000 & & p = 0.000 & p = 0.000 \\
\hline
Bax/Bcl-2 & & p = 0.038 & & & p = 0.036 \\
\hline
CyD1 & p = 0.000 & p = 0.000 & & & p = 0.000 & p = 0.012 \\
\hline
HSF1 & p = 0.000 & p = 0.008 & & & p = 0.000 \\
\hline
PAcP & p = 0.000 & p = 0.000 & & & p = 0.000 & p = 0.005 \\
\hline
p21 & & p = 0.000 & p = 0.000 & p = 0.000 & p = 0.000 & p = 0.000 \\
\hline
TM & p = 0.035 & p = 0.000 & p = 0.000 & & p = 0.000 & p = 0.000 \\
\hline
\end{tabular}}
\end{table}
|
PMC4440734_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Genotype} & \textbf{Rooting (\%)} & \textbf{No. roots} \\
\hline
3M & 98az & 17.0a \\
\hline
C10 & 100a & 14.5ab \\
\hline
B6 & 100a & 9.6bc \\
\hline
MP11 & 78b & 6.2c \\
\hline
\end{tabular}}
\end{table}
|
PMC5881154_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Species} & \textbf{Latin name} & \textbf{Counts} \\
\hline
Ginseng Radix et Rhizoma & Panax ginseng C. A. Me & 79943 \\
\hline
Achyranthis bidentatae Radix & Achyranthes bidentata B1. & 157189 \\
\hline
Glycyrrhiz Radix et Rhizoma & Glycyrrhiza uralensis Fisch. & 72834 \\
\hline
Coicis Semen & Coix lacryma-jobi L. var. ma-yuen (Roman.) Stapf & 419 \\
\hline
Phellodendron chinense Cotex & Phellodendron chinense Schneid & 20 \\
\hline
\end{tabular}}
\end{table}
|
PMC5974330_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Pop} & & \textbf{N} & \textbf{Na} & \textbf{Ne} & \textbf{Ho} & \textbf{He} & \textbf{F} \\
\hline
Normal & Mean & 148 & 5.939 & 3.230 & 0.612 & 0.638 & 0.038 \\
\hline
& SE & & 0.351 & 0.212 & 0.027 & 0.028 & 0.011 \\
\hline
Normal + carriers & Mean & 168 & 5.970 & 3.240 & 0.616 & 0.640 & 0.038 \\
\hline
& SE & & 0.349 & 0.211 & 0.027 & 0.028 & 0.011 \\
\hline
\end{tabular}}
\end{table}
|
PMC5699110_table_5
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.